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1. INTRODUCTION 
 
1.1 GLIAL CELLS 
 
The nervous system is composed of two major cell types: neurons and glia. Glial cells constitute 
90% of cells in the human brain and have been considered for a long time as passive supporting 
cells for neurons (1). However, there has been a growing interest in glia, and recent studies have 
provided convincing evidence that glia plays dynamic structural and signaling roles, both during 
the development as well as in adult and aging brains. The impairment of these properties are 
often present in most of the neurological conditions (2). 
Glial cells play critical roles in neuronal homeostasis through their physical properties, in 
particular they: 
• Perform a housekeeping role to remove extra neurotransmitters released by neurons 
during synaptic transmission and balance the ionic strength of the local neuronal 
environment. 
• Function as scavengers to remove debris after nerve injury or neuronal death. 
• Cooperate to form the blood–brain barrier that prevents large molecules/particles in the 
blood from entering the brain. 
• Produce myelin, which insulates nerve cell axons that conduct electrical signals. 
• Integrate neuronal inputs as well as release growth factors and neuromodulators, in 
association with synapses. 
There are three types of glial cells in the central nervous system (CNS): macroglia, which 
comprises astrocytes and oligodendrocytes, ependymal cells and microglia (Figure 1.1). 
 
 
Figure 1.1. Schematic representation of the different types of glial cells in the central nervous system (CNS) and 
their interactions, among themselves and with neurons. (Introduction to the Human Body, 7/e 2007 John 
Wiley & Sons). 
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1.1.1 MACROGLIA 
Macroglia originates from a single layer of proliferating neuroepithelial cells. These neural 
progenitor cells (NPC) line the ventricles, forming the ventricular zone (VZ). NPCs in the VZ 
proliferate and sequentially give rise to astrocytes and oligodendrocytes (3).  
ASTROCYTES 
 
Astrocytes are the most abundant glial cells with irregular star-shaped cell bodies and broad end-
feet on their processes (4). They can be divided into two main subtypes, protoplasmic or fibrous, 
on the basis of differences in their cellular morphology and anatomical location. Protoplasmic 
astrocytes are found throughout all gray matter and, as first demonstrated using classical silver 
impregnation techniques, exhibit a morphology of several stem branches that give rise to many 
finely branching processes in a uniform globoid distribution. Fibrous astrocytes are found 
throughout all white matter and exhibit a morphology characterized by many long fiber-like 
processes. Classical and modern neuroanatomical studies also indicate that both astrocyte 
subtypes make extensive contacts with blood vessels. Electron microscopic analyses revealed 
that the processes of protoplasmic astrocytes envelop synapses and that the processes of fibrous 
astrocytes contact nodes of Ranvier, and that both types of astrocytes form gap junctions 
between distal processes of neighboring astrocytes.  
Astrocytes express and secrete many signaling molecules that mediate synapse formation and 
synaptic transmission. They also express neurotransmitter receptors, through which they potently 
regulate neurotransmitter recycling at synaptic sites through the formation of “tripartite” 
synapses consisting of astroglial projections and neuronal pre- and postsynaptic terminals. 
Astrocytic end-feet are an essential constituent of the blood brain barrier (BBB). Through these 
widespread contact properties, astroglia have the ability to adjust blood flow for oxygen, ATP 
and glucose supplies, in addition to maintaining ionic concentrations in the extracellular matrix. 
Through the expression of aquaporin 4 water channels in the astrocytic vascular end-feet, 
astroglia play a vital role in the newly discovered glymphatic system, which is a brain drainage 
system implicated in the clearance of the amyloidβ Aβ and tau proteins (Figure
 
 1.2). 
Figure 1.1.1. Schematic representations that summarize astrocyte functions in healthy CNS (4). 
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Among the molecular marker that has been used for identification of astrocytes is the glial 
fibrillary acid protein (GFAP) that has become a prototypical marker for immunohistochemical 
identification of astrocytes. Other markers include glutamine synthetase and S100β. 
Astrocytes become reactive in response to various triggers, and this process is associated with 
morphological, molecular and functional changes. Reactive astrogliosis, marked by GFAP 
immunoreactivity, is a common feature associated with both acute brain injury and chronic 
neurological conditions. 
OLIGODENDROCYTES 
 
The term oligodendroglia was introduced by Rio Hortega to describe those neuroglial cells that 
show few processes in material stained by metallic impregnation techniques (2). The 
oligodendrocyte is mainly a myelin-forming cell, but there are also satellite oligodendrocytes  
that may not be directly connected to the myelin sheath. Satellite oligodendrocytes are 
perineuronal and may serve to regulate the microenvironment around neurons. A number of 
features consistently distinguish oligodendrocytes from astrocytes, in particular their smaller 
size, the greater density of both cytoplasm and nucleus (with dense chromatin), the absence of 
GFAP and of glycogen in the cytoplasm, and the presence of a large number of microtubules (25 
nm in diameter) in their processes that may be involved in their stability. An oligodendrocyte 
extends many processes, each of which contacts and repeatedly envelopes a stretch of axon with 
subsequent condensation of this multispiral membrane-forming myelin. On the same axon, 
adjacent myelin segments belong to different oligodendrocytes. The number of processes that 
form myelin sheaths from a single oligodendrocyte varies according to the area of the CNS (5). 
 
1.1.2 EPENDYMAL CELLS  
 
Ependymal cells are ciliated cells that derives from the neuroectoderm (3). They constitute an 
epithelium, the ependyma, which lines the ventricles throughout the brain, including the dorsal 
part of the third ventricle next to the hypothalamus. There is a transitional zone at the middle of 
the third ventricle where another type of cells can be found, the tanycytes, specialized glial cells 
with long processes that directly access the circulation through fenestrations of the BBB.  
The morphology of ependymocytes is very characteristic as they have numerous cilia, although 
ependymal cells with a long basal body and only two cilia have been described in the lateral 
ventricular zone. These cells secrete cerebrospinal fluid (CSF), with their numerous cilia 
participating in the transport of this fluid. 
Ependymocytes play key roles in the central nervous system physiology. These roles depend on 
mechanisms related to cell polarity, sensory primary cilia, motile cilia, tight junctions, adherens 
junctions and gap junctions, machinery for endocytosis and molecule secretion, and water 
channels (5). 
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1.1.3 MICROGLIA 
 
Microglia is constituted by specialized macrophages of the central nervous system (CNS) that 
are distinguished from other glial cells by their origin, morphology, gene expression pattern and 
functions (2). 
Microglia constitutes 5–20% of total glial cells, depending on the specific region of the CNS. It 
is found either in the brain parenchyma, often with a typical ramified appearance, or as 
perivascular microglia closely attached to the vasculature and within the perivascular ECM. In 
contrast to neurons and other glial cells, microglia is of haematopoietic origin and acts as 
primary responding cells for pathogen infection and injury.  
These cells express many macrophage-associated markers, such as CD11b, CD14 and EGF-like 
module-containing mucin-like hormone receptor-like 1 (EMR1). Microglia exhibits several 
features that distinguishes it from other populations of macrophages, such as their ‘ramified’ 
branches that emerge from the cell body and communicate with surrounding neurons and other 
glial cells. Microglia rapidly responds to infectious and traumatic stimuli and adopts an 
‘amoeboid’ activated phenotype (6).  
Activated microglia produces many pro-inflammatory mediators, including cytokines, 
chemokines, reactive oxygen species (ROS) and nitric oxide, which contribute to the clearance 
of pathogen infections. However, prolonged or excessive microglial cell activation may result in 
pathological forms of inflammation that contribute to the progression of neurodegenerative and 
neoplastic diseases (7). 
 
1.2 GLIOMA 
 
Glioma is the most common primary malignant brain tumor and arises throughout the central 
nervous system (CNS) from glia (8). 
The incidence of primary brain tumors worldwide is approximately 7 per 100,000 individuals per 
year, accounting for about 2% of primary tumors and 7% of the years of life lost from cancer 
before the age of 70 (9). 
Histopathologically, gliomas can grossly be divided into astrocytic, oligodendrocytic, and 
ependymal phenotypes. Classification by the World Health Organization (WHO) distinguishes 
malignancy by grade (I-IV). The most common and biologically aggressive of these tumors is 
glioblastoma (GBM), (WHO) grade IV, and is defined by the hallmark features of uncontrolled 
cellular proliferation, diffuse infiltration, propensity for necrosis, robust angiogenesis, intense 
resistance to apoptosis, and rampant genomic instability (10). Despite implementation of  
multidisciplinary approaches which includes surgical resection, radiation and chemotherapy, 
survival rate is less than 5% at five years after treatment, and is worse in old patients (8). 
Furthermore these cancers exhibit resistance to new targeted therapeutic approaches against 
angiogenesis mechanism. These poor results drive on new opportunities for understanding the 
fundamental basis for development of this devastating disease and also novel therapies that, for 
the first time, portend meaningful clinical responses (11). 
While grade I glioma are characterized by an excellent prognosis, 70% of grade II low-grade 
gliomas, altough slow-growing tumours, will almost invariably transform over time to a more 
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malignant phenotype; besides, early diffuse infiltration of the surrounding brain renders them 
incurable by surgery (12). Recent advances highlight the cellular heterogeneity (13), and their 
classification based on phenotypic resemblance to normal glial cells (astrocytomas, 
oligodendrogliomas, mixed oligoastrocytomas) and pathological grading cannot predict the 
clinical development of disease. Recently, genomewide analyses from multiple platforms 
delineated new molecular classes of lower-grade gliomas that were able to prognostically 
stratifying grade II and grade III LGG (14; 15). However, the evidence that this classification is 
working on LGG only (being grade III glioma per se characterized by a worse prognosis, with 
respect to the grade II ones), is still missing. 
 
1.2.1 EPIDEMIOLOGY 
 
Central Nervous System (CNS) cancers comprise a group of different tumour entities 
anatomically close to each other but diverse in terms of morphology, site, molecular biology and 
clinical behavior and, presumably, etiology. 
In Europe, the standardized (World) incidence of primary CNS cancers ranges from 4.5 to 11.2 
cases per 100,000 men and from 1.6 to 8.5 per 100,000 women. The two most common CNS 
cancers, high-grade glioma and brain metastases occur more frequently during adulthood and 
especially among the elderly. In Europe, the peak of incidence is 18.5/100,000 in people aged ≥ 
65 years. The relative frequency of CNS tumors is however highest during childhood, when they 
account for 23% of all the cancers diagnosed. In adults the 5-year survival rate for the primary 
CNS cancers in Europe was 17% for males and 19% for females (1995–2002), with differences 
across European regions. Survivorship is higher for young European patients – 63% – than for 
the elderly ones (16). 
Gliomas represent 81% of malignant brain and CNS tumors. Their incidence rates vary 
significantly by histologic type, age at diagnosis, gender, race, ethnicity and geographic location. 
In general, gliomas are more common with increasing age, male gender, white race and non-
Hispanic ethnicity. The most common type of glioma is glioblastoma, which ranges in age- 
adjusted incidence rate from 0.59 to 3.69 per 100,000 persons depending on reporting 
country/organization. Anaplastic astrocytoma (WHO grade III) and GBM are highest in 
incidence among those 75-84 years old, but oligodendroglioma and oligoastrocytomas are most 
common in those 35-44 years old. 
Many potential risk factors for gliomas have been studied to date, but few provide explanation 
for the number of brain tumors identified. A meta-analysis conducted on a great number of 
patients population for use of mobile phones with a latency period of 10 years, give a consistent 
pattern of increased risk for acoustic neurinoma and glioma (17).   
For other potential risk factors, exposure to some substances, such pesticides, fertilizers, and 
therapeutic irradiation to the head are suggestive but not conclusive of a risk pattern for glioma 
(18). 
A very small proportion of glioma cases can be attributed to inherited genetic disorders. The 
genetic syndromes associated with the nervous system are: neurofibromatosis type 1, 
neurofibromatosis type 2 (associated to neurofibromin 1 and 2 genes mutations, respectively), 
Li-Fraumeni syndrome (associated to p53 gene mutations), Cowden disease (associated to 
Phosphatase and tensin homolog -PTEN- gene mutations) and Turcot syndrome (associated to 
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adenomatous polyposis coli -APC- gene mutations). They are characterized by the direct 
involvement of the underlying genetic abnormality in their pathogenesis and may have different 
clinical, histological and genetic features compared to their sporadic counterparts (19), (20).  
 
1.2.2 GLIOMA CLASSIFICATION 
 
Gliomas can be classified using different criteria.  
The international classification of human tumors published by the World Health Organization 
(WHO) was initiated through a resolution of the WHO Executive Board in 1956 and the World 
Health Assembly in 1957. Its objectives have remained the same until today: to establish a 
classification and grading of human tumors that is accepted and used worldwide. Without clearly 
defined histopathological and clinical diagnostic criteria, epidemiological studies and clinical 
trials could not be conducted beyond institutional and national boundaries. The last edition on 
the histological typing of tumours of the nervous system was edited by a group of 25 
pathologists and geneticists in November 2006 and the results of their deliberations and those of 
an additional 50 contributors are contained in the 2007 WHO classification of tumors of the 
central nervous system (9) (Table 1.1).  
Gliomas are: 
• classified histologically, immunohistochemically, and/or ultrastructurally as 
astrocytomas, oligodendrogliomas, or tumors with morphological features of both 
astrocytes and oligodendrocytes, termed oligoastrocytomas.  
• graded on a WHO consensus-derived scale of I to IV according to their degree of 
malignancy as judged by various histological features accompanied by genetic 
alterations. 
- grade I tumors are biologically benign and can be cured if they can be surgically 
resected;  
- grade II tumors are low-grade malignancies that may follow long clinical courses, but 
early diffuse infiltration of the surrounding brain renders them incurable by surgery;  
- grade III tumors exhibit increased anaplasia and proliferation over grade II tumors and 
are more rapidly fatal;  
- grade IV tumors exhibit more advanced features of malignancy, including vascular 
proliferation and necrosis, and as they are recalcitrant to radio/chemotherapy they are 
generally lethal within a year. 
WHO grade is one component of a combination of criteria used to predict a response to therapy 
and outcome. Other criteria include clinical findings, such as age of the patient, neurologic 
performance status and tumors location; radiological features such as contrast enhancement; 
extent of surgical resection; proliferation indices; and genetic alterations. As regards molecular 
abnormalities, large-scale genetic sequencing efforts have identified key genomic alterations 
across glial subtypes, including mutations in CIC, FUBP1, 1p/19q co-deletion, IDH1/2, TERT 
promoter, ATRX, and the alternative lengthening of  telomeres (ALT) phenotype (21). For this 
reason, recent and ongoing translational studies in neuro-oncology have investigated the role of 
molecular markers as potential predictors of outcome in patients (13). For each tumor entity, 
combinations of these parameters contribute to an overall estimate of prognosis. 
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Table 1.2.1. WHO Grading of Tumors of the Central Nervous System4. Gliomas are identified by the 
square red.  
 
Gliomas can be classified on the basis of their localization above or below the tentorium, that is 
the membrane that separates the cerebellum from the inferior portion of the occipital lobes. 
Supratentorial gliomas, above the tentorium, are common in adults, meanwhile infratentorial 
gliomas, below the tentorium, are more frequently in infants (22). 
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Gliomas are further categorized from a clinical point of view in (8): 
 
• Low-grade gliomas (LGG), which are categorized by the WHO as grade I and grade II; 
they  tend to have a low proliferative potential and are well differentiated;  
• High-grade gliomas (HGG), which are grade III or IV and have anaplastic features, high 
mitotic activity with or without vascular proliferation and necrosis.  
These subgroups correlate to epidemiologic readouts and are functional to predict prognosis, 
therapy and follow-up. However, it’s often difficult to distinguish between a LGG and a HGG. 
Moreover, as explained above, gliomas, in particular LGG, display a large degree of 
heterogeneity, both among tumors histopathologically similar and among tumor cells within the 
same tumor, making difficult to predict clinical outcome and hindering the decision-making 
process (12). 
In order to explore glioma heterogeneity possible gaining insights into possible novel 
prognostic/predictive factors and therapies, three different approaches have been recently 
exploited, for both LGG and HGG: wide and integrated genome analyses, study of the glioma 
microenvironment and study of glioma stem cells (GSCs). 
 
1.2.3 LOW-GRADE GLIOMA (LGG) 
 
Low-grade gliomas represent up to 30% of gliomas and affect patients at a younger age than 
high-grade gliomas. LGG are commonly located in or close to eloquent areas, i.e. those areas of 
the brain involved in motor, language, visuospatial and memory function. The 5-year overall 
(OS) and progression-free survival (PFS) rates in randomized studies range from 58% to 72% 
and 37% to 55%, respectively (23). 
LGG categories include subependymal giant cell astrocytoma, pilocytic astrocytoma, pilomyxoid 
astrocytoma, diffuse astrocytoma, pleomorphic xanthoastrocytoma, oligodendroglioma, 
oligoastrocytoma and certain ependymomas. Among these subtypes, diffuse astrocytomas, 
mixed oligoastrocytomas and oligodendroglioma are the most common. These tumors are 
improperly defined as benign because they have a slow growth rate and a high degree of cellular 
differentiation, but unlike pilocytic astrocytomas, they grow diffusely into the normal brain 
parenchyma and are prone to malignant progression (14). Although LGG are clinically stable over 
a long period of time, some of them eventually transform into higher-grade tumours (WHO 
grade III–IV) at some point during the course of the disease. It is estimated that about 70 % of 
grade II gliomas progresses to an anaplastic form within 5-10 years with aggressive clinical 
manifestation and fatal outcome (24), (25). Moreover, survival rate can range between 1 to 15 years 
and some LGG can be sensitive to standard therapies (26), (27).  
Therapeutic decisions in the management of patients with LGG (28) have traditionally been 
based on widely accepted clinical prognostic factors, which are: 
• Age over 40 years 
• Presence/absence of pre-operative neurological deficits 
• Tumor size 
Historically, standard care for LGG consists of surgical resection (if feasible) or biopsy and 
subsequent radiotherapy, yet alkylating chemotherapy and targeted drugs are increasingly 
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recognized as equivalent upfront treatment alternatives. However, complete neurosurgical 
resection is impossible, and the presence of residual tumor results in recurrence and malignant 
progression, albeit at highly variable intervals. Besides radiotherapy of the involved part of the 
brain, is not associated with an overall survival (OS) benefit but possibly with long-term 
sequelae, i. e. leucoencephalopathy and cognitive deficits, especially in patients with a favorable 
prognosis (27). 
Although diagnosis has traditionally been made on the basis of histology, it suffers from high 
intraobserver and interobserver variability, does not adequately predict clinical outcomes and it 
is impossible to distinguish a secondary glioblastoma, defined as a tumor that was previously 
diagnosed as a lower-grade glioma, from a primary tumor (13).  
Patient management is a challenge therefore clinicians increasingly rely on genetic classification 
to guide clinical decision-making. 
 
1.2.4 MOLECULAR ABNORMALITIES IN LOW-GRADE 
GLIOMA (LGG) 
 
Molecular abnormalities involve mutation of several genes, including isocitrate dehydrogenase 1 
(IDH 1) and 2 (IDH 2), TP53 (tumor protein p53), ATRX (alpha-thalassemia/mental retardation 
syndrome X-linked), telomerase reverse transcriptase (TERT) promoter, deletion of 
chromosomes 1p and 19q, O6-methylguanine-DNA methyltransferase (MGMT) promoter 
methylation status and  mutations in the v-raf murine sarcoma viral oncogene homolog B1 
(BRAF) oncogene (14), (29), (30), (31) (15). 
 
IDH1 AND IDH2 MUTATIONS 
 
The molecular aberrations most intensely investigated in LGG during the past few years are 
point mutations in the IDH1 and IDH2 genes. IDH normally catalyzes the oxidative 
decarboxylation of isocitrate, producing alpha-ketoglutarate and CO2. This enzyme has 3 
isoforms: IDH1, IDH2 and IDH3. IDH3 catalyzes the third step of the citric acid cycle within the 
mitochondria. IDH1 and IDH2 catalyze this same reaction, but outside of the context of the citric 
acid cycle. Whereas IDH3 reduces NAD+ to NADH in this process, IDH1 and IDH2 use 
NADP+ instead. IDH1 is the only isoform localized to the cytoplasm (28). When mutations occur 
in IDH1 or IDH2, the mutant enzyme develops a preferential affinity for alpha-ketoglutarate 
instead of isocitrate, which leads to the production and accumulation of the oncometabolite 2-
hydroxyglutarate. 
Both IDH1 and IDH2 mutations occur in infiltrating gliomas, though IDH2 mutations are much 
less common than IDH1 (32). IDH1 mutations are found in approximately 70–80% of histologic 
grades II and III infiltrating gliomas and secondary GBMs, yet are much less frequent in primary 
GBM(about 5%) (14), (26), (28), (33), (34), (35). These mutations aid diagnosis of diffuse brain lesions and 
differentiate diffuse LGG from pilocytic astrocytomas or ependymomas that lack IDH mutations. 
Moreover, IDH1/IDH2 mutations have been confirmed as early mutations in LGG and are 
associated with a younger age.  
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IDH mutant gliomas progress more slowly over time than those lacking IDH mutations, 
suggesting that these are biologically distinct forms of disease. Therefore, diffuse gliomas with 
IDH mutations are associated with a better prognosis, grade for grade, than those without (13). 
The importance of IDH mutations was recently corroborated by the identification of a CpG 
island methylator phenotype in a distinct subset of gliomas (G-CIMP), characterized by 
hypermethylation at a large number of CpG loci including the MGMT promoter-associated CpG 
island. Patients with G-CIMP are younger at the time of diagnosis and have a significantly 
longer survival. Moreover, the G-CIMP is more prevalent among LGG and tightly associated 
with IDH1 mutations. Most importantly, the IDH1 point mutation R132H was recently 
demonstrated to be causative to G-CIMP by remodelling the tumour methylome and 
transcriptome. It will be intriguing to see whether G-CIMP stands its ground as a prognostic or 
even a predictive biomarker in the framework of translational studies to be conducted in the near 
future (34), (35). 
 
O6-METHYLGUANINE-DNA METHYLTRANSFERASE (MGMT) PROMOTER 
METHYLATION 
 
Standard therapy for GBM includes radiation and chemotherapy with temozolomide, which acts 
by crosslinking DNA by alkylating multiple sites including the O position of guanine (36). DNA 
crosslinking is reversed by the DNA repair enzyme MGMT. Therefore, low levels of MGMT 
would be expected to enhance response to alkylating agents. The expression level of MGMT is 
determined in large part by the methylation status of the gene’s promoter. In low grade diffuse 
astrocytomas and secondary GBM, MGMT promotermethylation is tightly correlated with TP53 
mutation and overexpression of the p53 protein (33), (37). A recent study found that MGMT 
promoter hypermethylation is significantly associated with IDH1/IDH2 mutations in grade II–III 
gliomas, whereas it had a borderline association with 1p deletion in oligodendrogliomas (38). 
 
IDH MUTATIONS AND 1p/19q CO-DELETION 
 
The loss of chromosomal material on 1p and/or 19q resulting from an unbalanced translocation, 
named loss of heterozygosity (LOH) 1p/19q, most strongly associated with oligodendroglial 
brain tumours, was first recognized as a predictor of chemosensitivity and later on of sensitivity 
to radiotherapy, and as a prognostic factor as well. More recent interpretations have emphasized 
that the combination of IDH mutation and 1p/19q co-deletion is the molecular signature of LGG 
rather than an association (21). 
Recently, the Cancer Genome Atlas project (TCGA) have characterized LGG (13), (39). TCGA is a 
global genomic profiling project that utilized high-throughput microarray technologies to 
identify molecular subtype classifications of cancers, multigene clinical predictors, new targets 
for drug therapy, and predictive markers for these therapies. The project delineated three 
molecular classes of 293 lower-grade gliomas from adults that were more concordant with IDH, 
1p/19q codeletion, and TP53 status than with histologic class (14). 
The results are so described:  
• LLG with an IDH mutation and no 1p/19q codeletion (94%) harbored TP53 
mutations, which suggests that this tumor class is defined by a loss of p53 function. 
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Inactivating alterations of ATRX were frequent (86%) and included mutations (79%), 
deletions (3%), gene fusion (2%), or a combination of these events (2%). 
• LLG with an IDH mutation and 1p/19q codeletion presented CIC (capicua 
transcriptional repressor) mutations in 62%, FUBP1 (far upstream element (FUSE) 
binding protein 1) mutations in 29%, NOTCH1mutations  (31%) and TERT (telomerase 
reverse transcriptase) promoter mutations in 96%; ATRX mutations were rare in these 
tumors, a finding consistent with the mutual exclusivity of ATRX and TERT mutations.  
• LLG with wild-type IDH had more mutations than did samples with an IDH mutation 
and 1p/19q codeletion or  those with an IDH mutation and no 1p/19q codeletion and 
showed remarkable genomic and clinical similarity to primary (wildtype IDH) 
glioblastoma (Figures
 
 1.2.1 and 1.2.2). 
 
Figure 1.2.1. Summary of major findings. Schematic representation that summarizes the major molecular 
findings and distinct clinical presentations of grade II and grade III gliomas. GBM denotes glioblastoma, and LGG 
lower-grade glioma (14). 
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Figure 1.2.2.
Similarly, another recent study defined five glioma molecular groups with the use of three 
alterations: mutations in the TERT promoter, mutations in IDH, and codeletion of chromosome 
arms 1p and 19q (1p/19q codeletion). The five groups are called: triple-positive, with TERT and 
IDH1 mutations, with TERT mutations only, with IDH mutations only, triple-negative (15). 
The results are so described:  
 Clinical outcomes. Panel shows Kaplan–Meier estimates of overall survival among patients with 
LGGs that are classified according to IDH mutation and 1p/19q codeletion status. GBM samples classified according 
to IDH mutation status are also included (14). 
• Triple-positive gliomas are most strongly associated with the oligodendroglial histologic 
type and have better overall survival. 
• Gliomas with TERT and IDH1 mutations without an accompanying 1p/19q codeletion 
are relatively rare, accounting for 4% of all gliomas in the combined data set, and carried 
a lower risk for patient mortality.  
• Gliomas with only TERT mutations are primarily grade IV gliomas; however, 9.6% in 
this study were grade II or III. Grade II or III gliomas in this group have an aggressive 
course and are associated with poor survival, which suggests the need for early adjuvant 
therapies and meticulous follow-up. 
• Gliomas with only IDH mutations have the earliest mean age at onset (37 years) and an 
intermediate prognosis; they also account for half of all patients who have gliomas with 
an oligodendroglial component and two thirds of those who have grade II or III 
astrocytomas. These tumors almost always acquire mutations in TP53 and ATRX.  On 
the basis of their uniform mutational profile, gliomas with only IDH mutations become 
an important group for experimental modeling and novel therapeutic discovery. 
• Triple-negative gliomas constitute 7% of grade II or III gliomas and 17% of grade IV 
gliomas. Although they typically develop in younger patients (approximately 10 years 
younger) than do gliomas with TERT mutations only, these two types of gliomas have a 
similar level of MGMT promoter methylation and similar associations with germline 
variants (Figure
 
 1.2.3). 
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Figure
Studies based on morphologic class have consistently shown that the large majority of grade II 
and III diffuse astrocytomas and secondary glioblastomas have TP53 mutations (32), (33). When 
restricted to IDH-mutated infiltrating astrocytomas, an even higher percentage has TP53 
mutations, since IDH wild-type diffuse gliomas have lower frequencies of TP53 mutation. In a 
study of 939 tumors of diverse histologies, 80% of IDH-mutated (IDH1 or IDH2) anaplastic 
astrocytomas and GBM also harbored TP53 mutations (32). Conversely, others have shown that 
63% of grade II diffuse astrocytomas that contained a TP53 mutation also harbored an IDH1 
mutation. More recently, The Cancer Genome Atlas project demonstrated that 94% of IDH 
mutant grade II and III diffuse gliomas that lacked 1p/19q co-deletion had TP53 mutations (39).  
 1.2.3. Overall survival of grade II and III gliomas. Adjusted Kaplan–Meier Estimates of Overall Survival 
in the five Glioma Molecular Groups (15). 
 
As seen above, beside association between IDH mutation and 1p/19q co-deletion, there is a 
molecular subset defined by IDH mutation, TP53  mutations and loss of ATRX, a gene that 
encodes a chromatin-remodeling regulator. 
The combination of IDH and TP53 mutations is strongly coupled to inactivating alterations in 
ATRX. In one large analysis of 363 brain tumors, ATRX mutations were most frequent in grades 
II and III astrocytomas and oligoastrocytomas (67–73%) as well as secondary GBM (57%), but 
were uncommon in primary GBM, oligodendroglial tumors and pediatric GBM (4%, 14% and 
20%, respectively) (34). Nearly all diffuse gliomas with an ATRX mutation had an IDH1 mutation 
as well. In tumors with IDH and ATRX mutations present, 94% had a TP53 mutation. ATRX 
mutations are associated with the Alternative Lengthening of Telomeres (ALT) phenotype (34), an 
alternative mechanism for maintaining telomere length in tumors that do not have constitutive 
telomerase activity. In establishing the diagnosis of an IDH mutant diffuse glioma, loss of 
immunohistochemical staining for ATRX in neoplastic cells is an excellent surrogate for ATRX 
gene inactivation and supports the diagnosis of an astrocytoma. The evidence to date indicates 
that the molecular signature of IDH mutant astrocytoma includes TP53 mutation and ATRX 
alteration and is associated with ALT (14), (35), (39). 
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With this emerging definition of disease, the optimal morphologic or molecular prognostic and 
predictive markers will need to be defined. 
 
1.2.5 HIGH-GRADE GLIOMA (HGG) 
 
High-grade gliomas are characterized by their invasiveness and lack of differentiation. This 
group of gliomas includes anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic 
oligoastrocytoma, which are grade III, and glioblastoma (GBM), which is grade IV (36). GBM 
carries the worst prognosis, while pure oligodendroglioma has a protracted natural history and 
better outcome, and excellent response to therapy. Prognosis of mixed anaplastic 
oligoastrocytoma and anaplastic astrocytoma is intermediate between GBM and pure anaplastic 
oligodendroglioma (40). 
The recent trend towards genomic profiling of gliomas has led to the exploration of classifying 
lesions into molecular groups based on multi-gene predictors. This classification may allow for 
the identification of new targets with the additional benefits of predictive markers for target 
therapies. The Cancer Genome Atlas (TCGA) database first sequenced GBM in 2008 (37).  
Genetic abnormalities involving gain and loss of heterozygosity (LOH) of chromosome 7 and 10 
respectively with associated EGFR amplification and PTEN loss drive tumorigenesis in high-
grade gliomas. Similarly, the presence of mutations involved in the receptor tyrosine kinase 
(RTK), p53, or RB pathways has similar associations with high-grade gliomas. Frequent 
mutations of cell cycle regulatory genes in glioma have underscored the importance of these 
genes in cellular proliferation and senescence. The RB and p53 pathways, which regulate the cell 
cycle primarily by governing the G1-to-S-phase transition, are major targets of inactivating 
mutations in GBM. The absence of these cell cycle guardians renders tumors particularly 
susceptible to inappropriate cell division driven by constitutively active mitogenic signaling 
effectors, such as phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase 
(MAPK). Ultimately, patient specific data from high throughput screening will be utilized for 
diagnosis, prognostication, and patient-specific therapy based on the unique genetic signature of 
their neoplasm. 
All GBM can be divided into two subtypes based on the presence of absence of a precursor 
lesion of a lower grade. Primary GBM is the most common type (>90%) and diagnosed as a de 
novo lesion without progression from a lower grade tumor in older patients (>60 years). 
Secondary GBMs result from progression of LGGs (WHO grade II/III) and are commonly found 
as a recurrence in younger patients (Figure 1.2.4). The time to GBM progression from a grade II 
in contrast to a grade III lesion is also longer (5 and 2 years respectively) (41), (42). 
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Figure
Analysis of GBM genomics reveals multiple tumor suppressor and oncogenes that are inactive 
and active, respectively, during tumor progression and de novo formation (43). The three main 
pathways implicated in GBM formation are: RTK-RAS-MAPK PI3KA, the p53 pathway, and 
the RB pathway (
 1.2.4. Molecular abnormalities in primary and secondary GBM (32). 
 
Figure 1.2.5).  
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Figure
In addition to the core signaling pathways identified through genome-wide screening studies, 
Harsh et al. recently reported that heterozygous deletion of the NF-κB inhibitor α (NFKBIA) 
gene was present in GBM (44). The NFKBIA gene encodes the protein IκBα, a crucial negative 
regulator in the canonical NF-κB signaling pathway. Under basal conditions, IκBα sequesters the 
NF-κB transcription factor heterodimer (p50/p65) in the cytoplasm. Upon stimulation with 
ligand such as tumor necrosis factor α (TNF-α) or lipopolysaccharide (LPS), IκBα is 
phosphorylated by the signalosome. This phosphorylation leads to rapid ubiquitination and 
degradation of IκBα, which releases the inhibition of NF-κB and allows translocation of p50/p65 
into the nucleus to activate transcription of downstream target genes, including many cytokines 
that can promote tumor growth and infiltration (45). 
 1.2.5. Core Signaling Pathways in Glioma Tumorigenesis. The receptor tyrosine kinase (RTK), p53, 
and Rb pathways are the core signaling pathways in glioma oncogenesis. Red indicates oncogenes that are either 
overexpressed or amplified in GBM samples, and blue indicates tumor suppressor genes that are somatically 
mutated or deleted (except for P27 and P21) (43). 
 
The gain of copies of chromosome 7 along with losses of chromosome 10 contributes to the 
EGFR and PTEN mutations commonly identified in primary GBM. IDH mutations, TP53 
mutations, and ATRX mutations are characteristic of secondary GBM. These mutations cluster 
specifically into gene expression profiles that are characteristic of recently described GBM 
subgroups. 
In GBM, NFKBIA deletion and EGFR amplification are mutually exclusive, raising the 
possibility that the two genetic events converge on the same pathway. Indeed, overexpression of 
NFKBIA reduced the viability of primary glioma cells in which NFKBIA was downregulated or 
EGFR was upregulated (44). In addition, both genetic events were associated with similar 
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prognostic outcome, which is inferior to that of patients with normal expression levels of these 
two genes. However, the detailed molecular mechanism for the role of NF-κB in glioma 
development and progression and its connection with EGFR signaling remain to be investigated. 
Researchers have examined DNA, mRNA, microRNA and epigenetic profiling to identify 
multiple glioma subtypes with different clinical outcomes (46). In the case of GBM, two major 
studies of the TCGA data identified three major subtypes. Two of the subgroups consistently 
replicate similar profiles in various studies and are in stark contrast to each other: proneural and 
mesenchymal. Proneural GBM is a secondary GBM that is present in young adults and has 
neuronal differentiation that is associated with better outcomes. Proneural GBM have IDH and 
TP53 mutations, a glioma-CpG island methylator phenotype, and a normal expression of 
EGFR/PTEN. This group represents close to 10% of all GBM, consistent with the known 
prevalence of secondary GBM. The mesenchymal GBM is common in older adults and is 
associated with a worse prognosis and characterized by neurofibromin 1 (NF1) loss or mutations 
(Neurofibromin acts as a tumor suppressor protein), abnormalities in Akt signaling, increased 
expression of angiogenic peptides, and overexpression of genes related to motility, the 
extracellular matrix, and cell adhesion. The final TCGA subtypes are the neural and the classical 
ones that are associated with PTEN loss and EGFR amplification and constitute the majority of 
GBM. 
 
1.3 GLIOMA STEM CELLS (GSC) IN HGG AND LGG 
 
The cancer stem cell theory postulates that tumors are sustained by a cell population with 
specific features, such as self-renewal ability and the capacity to give rise to a heterogeneous 
mass of tumor cells. Glioma stem cells (GSCs) were among the first cancer stem cell (CSC) that 
have been described in solid tumor (47), (48). It was reported that as few as 100 CD133+ GSCs, 
could give rise to tumors that recapitulated the parental tumors when implanted into 
immunodeficient mice, whereas as many as 1,000,000 CD133- GSC could not (47). This evidence 
indicated that only a selected cell population is responsible for sustaining and propagating 
tumors. Existence of GSC, then, could explain the gliomas resistance to existing therapies. 
According to their name, GSC should be cells with stemcell-like properties present within all 
types of glioma. However, most studies describe GSC isolated from primary glioblastomas (47), 
(48), (49), (50), (51), and whereas a few describe stem-like cells obtained from low-grade gliomas 
(LGGs) (47), several others report that no stem-cell-like population could be established from 
LGGs or even secondary glioblastomas (52), (53). Several factors might underlie the difficulty in 
isolating LGG stem cells. One possible explanation is that the number of stem-like cells might be 
proportional to the degree of malignancy, with grade I gliomas having few stem cells and 
secondary glioblastomas in the incipient phase having fewer GSC than primary glioblastomas. 
Alternatively, the current isolation and culture techniques, namely neurosphere formation in 
growth-factor-supplemented medium, may enrich for glioblastoma stem cells but may not be 
permissive for LGG stem cells. LGG stem cells might thus require soluble factors other than 
basic fibroblast growth factor and epidermal growth factor for their maintenance, or their 
dependence on the in vivo niche might be greater than that of glioblastoma stem cells (54). 
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GSC are not necessarily the cells of origin for the initial tumor: GSC isolated from human 
specimens act as glioma-initiating cells (GIC) in experimental models, a fact that sometimes 
leads to reciprocal use of these terms. However, present knowledge suggests that whereas glioma 
cells of origin, GIC, and GSC might have overlapping characteristics, they are not identical 
entities. Despite continued efforts, there is yet no definite answer as to what type of cell 
constitutes the cell of origin for malignant gliomas. Theoretically, glioma cells of origin are cells 
that give rise to the initial tumor. They are the cells that undergo the initial transformation events 
and acquire just enough tumorigenic capacity to escape control mechanisms and proliferate. 
They might, but do not necessarily, include cells that will later sustain the tumor, the GSC (54). 
Given that GBM are already highly heterogeneous at the time of diagnosis, retrospective analysis 
of clinical specimens is poorly suited to the unequivocal identification of a cell of origin. 
Analysis of animal models is therefore useful to complement the available information regarding 
the initial phase of GBM. A recent study used a murine glioblastoma model based on genetically 
modified neural stem cells (NSCs). The tumor cells isolated from the allografts and sorted for 
GFP expression were propagated as tumorspheres. These cells were serially transplantable;  they 
possessed self-renewal and differentiation potential and they truly represented the cell population 
that propagated the initial tumor. They could therefore be considered true GSC (54).  
Another characteristic of GSC, inferred from the properties of normal tissue stem cells and CSC 
of hematologic malignancies, is that they exist in and are protected by specific environments, the 
stem cell niches. Experimental data support this proposition and for GSC both perivascular and 
hypoxic niches have been described as such niches (see next paragraph). Whereas these 
observations require further validation, the niche represents an attractive target when considering 
future therapies. 
 
          Table 1.3 Similarities and differences between the terms GSCs, glioma cells of origin, and GICs (54). 
 
Regarding LGG, evidences that murine oligodendroglioma arises from NG2-expressing cells in 
white matter regions, rather than NSC, has been recently given by Weiss’s group, that linked the 
therapy-responsive nature of this tumor to a progenitor origin (55). Specifically, Authors 
demonstrated that NG2+ oligodendroglioma cells expressed genes and proteins associated with 
OPC rather than NSC, that NG2+ oligodendroglioma cells showed limited sphere-formation, 
consistent with a progenitor population, and that NG2+ oligodendroglioma cells were lineage 
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restricted, being able to differentiate only into oligodendroglial derivatives. Importantly, NG2-
expressing cells, from both mouse and human oligodendroglioma, displayed high in vivo 
tumorigenicity and were sensitive to both alkylating and differentiating agents (55). Finally, they 
showed that these oligodendroglioma cells were neither chemoresistant nor quiescent and 
suggested that a progenitor origin for these cells could explain their chemosensitivity. Similarly, 
to analyze if OPC could serve as cell of origin for glioma, Lindberg et al. developed a new tv-a 
transgenic mouse line, Ctv-a, in which viral infection could be targeted to OPC expressing 2’, 3’-
cyclic nucleotide 3’-phosphodiesterase (CNP) (56). CNP is a highly specific marker that in the 
central nervous system is only expressed late in OPC development and in mature 
oligodendrocytes. With the Ctv-a mouse Authors could induce low-grade oligodendroglioma 
with RCAS-PDGF-B showing that the cell of origin for oligodendroglioma may be a committed 
glial progenitor cell (56).  
In conclusion, several experimental evidences point to the fact that the cell of origin of low-
grade gliomas has not been unequivocally identified. Nevertheless, establishing the cellular 
origin can be essential to give a more accurate representation of the biological properties of a 
particular glioma and thereby a better prediction of response to different therapeutic strategies 
(57). 
1.4 CANCER STEM CELL NICHE 
 
Niches are specialized microenvironments that regulate adult stem cell fate by providing cues in 
the form of both cell-cell contacts and secreted factors. Normal niches are comprised of 
fibroblastic cells, immune cells, endothelial and perivascular cells or their progenitors, 
extracellular matrix (ECM) components, and networks of cytokines and growth factors (58). The 
CSC niche itself is a part of the tumor microenvironment (TME), which is a collective term for 
the adjacent stroma along with the normal counterparts of the tumorigenic cells. Non-CSC tumor 
cells are also part the CSC niche. During the progression of tumors to a more malignant state, 
cells within the CSC niche produce factors that stimulate CSC self-renewal, induce angiogenesis, 
and recruit immune and other stromal cells that secrete additional factors to promote tumor cell 
invasion and metastasis. 
In brain tumors the small population of tumor cells within the heterogeneous tumor mass with 
stem-like character is called brain tumor stem cell (BTSC). It is assumed that BTSC arise from 
stem/progenitor cells that have acquired various genetic and epigenetic alterations, enabling 
them to undergo neoplastic transformation and escape from vascular niche control. Alternatively, 
uncontrolled proliferation and transformation of BTSC may occur by deregulation of external 
signaling factors within the vascular niche (59), (60)(figure 1.4). 
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Figure
In the primary tumor, hypoxia develops within the tumor mass due to impaired vascularization, 
and reactive oxygen species (ROS) are increased (62), (63). Both hypoxia and ROS up-regulate the 
CSC stress signaling pathways to enhance cancer cell survival and maintain cancer cell stemness 
(64). Hypoxia further promotes CSC survival and epithelial-to-mesenchymal transition (EMT) 
through ROS-activated stress response pathways and through ROS-induced TGF- β and TNF-α 
signaling pathways. Activation of TGF-β as well as WNT signaling pathways by hypoxia 
induces stemness by promoting an undifferentiated state in tumor cells. In various solid cancers, 
endothelial cells (EC) promote self-renewal of CSC by direct cell-cell contact or by nitric oxide 
(NO) production via the NOTCH signaling pathway. Hypoxia-inducible factor 1 alpha (HIF-1α) 
also can directly increase NOTCH signaling. HIF-1α antagonizes Myelocytomatosis viral 
oncogene homolog (c-Myc) activation, thus slowing down cell-cycle progression to protect 
CSCs from DNA damage and enhance stemness (65). Hypoxia induces CSC to express hypoxia-
inducible factors (HIF), which are regulated and stabilized by TGF- β (66). The HIF genes are the 
primary factors for driving angiogenesis via induction of Vascular Endotelial Growth Factor 
(VEGF). Under hypoxia, both ECs and CSCs produce VEGF to stimulate tumor angiogenesis. In 
the hypoxic regions of the tumor, VEGF-A can recruit monocytes and macrophages (67). 
Ultimately, blood vessels and their EC and hypoxia and its factors are the principal actors for the 
CSC survival in the niche and therefore for the tumor growth. 
 1.4. Two microenvironments of brain tumor stem cells: vascular and hypoxic niches regulated by various 
signaling modes. BTSC: brain tumor stem cell, HIF: hypoxia-inducible factor, EC: endothelial cell (61). 
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A characteristic feature of high-grade character in gliomas is the presence of microvascular 
proliferating structures. These angiogenic entities represent regions of hyper-proliferative tumor 
stromal and endothelial cells. The brain tumor perivascular niche (PVN) (68), defined as the area 
that borders angiogenic/tumor microvascular structures, is a prime location for GSC. Recent data 
suggest that establishment of the brain tumor PVN facilitates expansion and differentiation of 
GSC. Indeed, the density of these PVN regions appeared to correlate with the number of GSC 
across several brain tumor subtypes including oligodendrogliomas and glioblastomas. 
A similar study identified PVN regions in medulloblastomas as prime locations for GSC that 
express both nestin and notch. These nestin-expressing GSC with respect to the tumor bulk, 
preferentially survived radiotherapy thus allowing repopulation and regeneration of the tumor 
after therapy. Several reports identify a variety of mechanisms that mediate these radioresistant 
effects. These studies highlight the growing recognition of the PVN as a critical participant in 
GSC regulation (69). 
The major cell types known to reside in the brain tumor PVN (69), are pericytes, immune cells 
including lymphocytes, macrophages and microglia, astrocytes, fibroblasts and endothelial cells 
that line the vasculature. Each of these individual cell types makes distinct contributions to tumor 
progression by either contributing to the formation and stability of the microenvironment that 
supports the GSC population or by promoting conditions within the niche that facilitates tumor 
progression. In summary, the perivascular niche is a complex environment. It is composed of 
multiple cell types, some neoplastic cells derived from the tumor itself and other non-neoplastic 
cells derived from the stroma. The interplay between these cell types regulates differentiation 
and tumor progression. 
 
1.5 TUMOR MICROENVIRONMENT (TME) 
 
As explained above, the term tumor microenvironment (TME) is a collective term that includes 
the tumor’s surrounding and supportive stroma, different cells of non-tumor origin (e.g. effectors 
of the immune system, fibroblast, EC) and soluble factors, including tumor- and stroma-derived 
extracellular vesicles (70). In normal epithelial tissues, homeostasis is maintained by a correct 
interpretation of the growth factor signaling present in the extracellular matrix (ECM) context. 
This control can be lost through impairment of the communication mechanisms between the 
epithelium and the surrounding stroma (71)(Figure 1.5). For example, an epithelial cell might 
incorrectly initiate a signal into the stroma resulting in the stromal production of a growth factor 
that, in turn, can stimulate the incorrect proliferation of neighboring epithelial cells. 
Alternatively, an aberrant matrix component produced by stromal cells in response to a local 
stress might be perceived by neighboring cells as a signal to grow or to enter a new 
developmental pathway. Under normal homeostasis, these mistakes are corrected by cell cycle 
arrest or apoptotic cell death. Occasionally, if the abnormal signal persists, the behavior can 
become increasingly unbalanced, creating a growing, interdependent, heterogeneous tissue, 
defined as a tumor by its ability to grow and by its unresponsiveness to normal physiological 
controls.  
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Figure
As mentioned, TME is composed of both non-cellular (proteins, proteases, cytokines, etc.) and 
cellular components such fibroblasts, endothelial, immune cells and cancer associated fibroblasts 
(CAF) (72).  
 1.5. Tumorigenesis mechanisms. Tumor production can be the product of epithelial mutations that 
create an expanding, reactive tumor. However, it is also possible for mutations or environmental factors that 
create a reactive stroma in turn inducing an unstable epithelium thus favoring tumorigenesis through the 
establishment of epithelial mutations (71). 
 
The role of CAF in tumour progression is multifaceted as they can either inhibit or promote 
malignant growth. CAF retain a major role in ECM remodelling since they are mainly 
responsible for the production of ECM proteins (i.e. collagens, fibronectin) as well as proteases 
and other enzymes involved in the posttranscriptional modification of  ECM proteins themselves 
(72). In solid tumors, an increased matrix deposition and a concurrent, progressive stiffening of 
ECM are commonly observed. Two interactive pathways are established in the cross talk linking 
cancer and stromal cells (Figure
• the efferent pathway, where cancer cells prompt a reactive response in the stroma; 
 1.5.1):  
• the afferent pathway, where the activated stromal cells influence cancer cell 
malignancy. 
 
In the efferent pathway, tumour growth factor-1 (TGF-β1) is one of the major pro-fibrotic 
tumour cell derived factors affecting CAF activation. Nevertheless, PDGF-α/β, basic fibroblast 
growth factor (bFGF) or interleukin (IL)-6 can also be secreted by cancer cells to activate CAF. 
The activation is a redox-regulated process. TGF-β1 leads to the generation of ROS in CAF, 
which are responsible for messengers for their achievement of miofibroblasts phenotype and for 
the downregulation of gap junctions, promoting tumor activity (73). This transdifferentiation of 
CAF is commonly identified as mesenchymal–mesenchymal transition (MMT) (74). 
In the afferent pathway CAF produce a series of growth factors and cytokines, such Hepatocyte 
Growth Factor (HGF), Epidermal Growth Factor (EGF), bFGF and IL-6, MMP and SDF-1 that 
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sustain tumor progression. In particular, HGF gives rise to an increased resistance of tumor cells 
to conventional tyrosine kinase inhibitors against EGF receptor (75). 
Figure 
The continuously evolving and dynamic interplay between the tumor and its environment is 
finally responsible for the tumor progression since it progressively allow tumor cells to acquire 
new properties evasion of  natural anticancer mechanisms, infiltration, chemo-resistance) (70) (76) 
that are hallmark of cancer. 
 
1.5.1. Interplay between CAFs and tumour cells: efferent and afferent pathways (72). 
 
1.6 GLIOMA MICROENVIRONMENT  
1.6.1 TUMOR MICROENVIRONMENT CELLS 
 
The microenvironment of glioma is composed of several stromal cell types, which are believed 
to make distinct contributions to tumor progression and invasion. These cells include but are not 
limited to astrocytes, macrophages, pericytes, fibroblasts and endothelial cells (69)(Figure 1.6.1). 
Figure
Pericytes are reportedly derived from mesenchymal stem cells or neural crest cells. They 
surround, stabilize and maintain the integrity of the walls of newly developed vasculature. In the 
 1.6.1. Microenvironment of gliomas (69)(BTSC=brain tumor stem cells). 
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brain, pericytes have also been reported to be involved in immunological functions. They tend to 
be largely localized to microvessels where they are tightly associated with endothelial cells, 
separated only by a shared basement membrane. In addition, a codependent relationship appears 
to exist between pericytes and endothelial cells where they can each influence the mitotic 
activities of one another. Pericytes express various markers some of which include, nerve/glial 
antigen 2 proteoglycan (NG2), α-smooth muscle actin (α-SMA), desmin and platelet- derived 
growth factor receptor β (PDGFRβ). However, none of these markers are absolutely specific for 
pericytes and their expression varies within specific tissues and developmental stages. Previous 
studies suggested a role for pericytes in microvascular proliferation in tumors. Pericyte 
recruitment has been identified to contribute to tumor vessel stabilization and survival of the 
vascular niche in pancreatic, melanoma and brain tumors. In addition, in gliomas and other 
malignant human brain tumors, perivascular localized pericytes are believed to play a critical 
role in shaping the angio-architecture of the tumor vascular niche (69). 
Fibroblasts have been shown to play an important role in tumor progression in other cancers. 
Fibroblasts localized to the brain tumor microenvironment have been identified to promote the 
invasion of brain tumor cells. The expression of matrix metalloproteases is critical for 
breakdown of the ECM for tumor invasion. Fibroblasts were shown to produce and mediate 
activation of proMMP-2, a metalloproteinase associated with increased invasiveness and 
malignant progression of gliomas (69). 
Astrocytes, in the normal brain, function as support cells as well as bonafide stem cells that 
express GFAP. In the context of the brain tumor microenvironment, astrocytes have been 
implicated in the progression of brain tumors. Reactive astrocytes are frequently associated with 
glioma cells in the central nervous system. Tumor-associated astrocytes have been demonstrated 
to mediate glioblastoma cell invasion via activation of proMMP2, a metalloproteinase that plays 
a critical role in glioma invasion (68).  
Perivascular astrocytes are closely associated with the endothelium. This close association is tied 
to its critical function in the induction and maintenance of the blood brain barrier (BBB). 
Crosstalk between perivascular astrocytes and endothelial cells can upregulate the expression of 
tight junction proteins, GLUT1 and Pgp transporters and BBB-associated enzyme activities of 
endothelial cells. These interactions ultimately enhance the stability of the vascular niche to 
support NSC. Some studies suggest that endothelial cells may mediate growth and differentiation 
of perivascular astrocytes (69).  
Resident macrophages of the brain are termed microglia (77), (78). These cells invade the brain 
early in development and differentiate into the so-called resident, ramified microglia. 
Historically, the presence of these immune cells in gliomas was postulated as a host defense 
mechanism to suppress dividing neoplastic cells: however, recent studies have identified glioma 
cells to play a direct role in recruitment of immune cells into tumors to support tumor growth. 
Macrophage recruitment to brain tumors is suggested to be a primary source of cytokines and 
other mediators that promote glioma proliferation and migration. 
A recent study, conducted by our research group, demonstrates that TME, both in LGG and in 
HGG, contains a population of nontumorigenic stem cells able to increase in vitro the GSC 
aggressiveness (79). These cells, named GASC (Glioma-Associated Stem Cells), present 
mesenchymal features and display aberrant growth properties in vitro. Nevertheless, they differ  
from GSC, since they are devoid of the genetic alterations characterizing the glioma of origin, 
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and are not able to originate a tumor when injected in vivo. Their aberrant growth reminds the 
distinguishing features of TAF which are characterized by the ability to modify the biological 
properties of tumor cell through the release of exosomes (Figure
 
 1.6.2). These latter are 
membrane vesicles that originate in multivesicular bodies and are released in the extracellular 
space and in the body fluids from many cell types and, through their content in biologically 
active molecules (e.g., proteins, mRNAs, and miRNAs), they act as a potent intercellular 
communication system (79). 
 
Figure
Importantly, the in vitro features of GASC were the strongest predictor of LGG patients’ overall 
survival and malignant progression free survival outperforming the state-of-the-art prognostic 
factors, including chromosome 1p-19q co-deletion, MGMT-promoter methilation and IDH1-
IDH2 gene mutation8, thus supporting the notion that this patient-based approach could provide a 
groundbreaking method to exploit novel strategies aimed at targeting the tumor stroma (79).  
 
 
 
 
 1.6.2. GSC, GASC and exosomes. GASC exert their tumor-supporting function through the release 
of exosomes. 
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1.6.1 SOLUBLE FACTORS INVOLVED IN GLIOMA 
PROGRESSION 
 
As seen above, TME is composed of a variable combination of tumor cells, immune cells, 
inflammatory cells, endothelial cells and ECM. A variety of cytokines and other substances such 
as chemokines and growth factors are produced by different cells in the local tumor environment, 
resulting in complex cell-cell interaction and regulation of the differentiation, activation, 
functioning and survival of multiple cell types (80). The interaction between cytokines and their 
receptor results in the formation of a comprehensive network at the tumor site that is primarily 
responsible for the overall progression of tumors, the spread of antitumor immune responses and 
the induction of tumor rejection (80). 
Cytokines are a heterogeneous group of soluble small polypeptide or glycoproteins that exert 
pleiotropic and redundant effects that promote the growth, differentiation and activation of 
normal cells. Immune cells are the major source of cytokines, but many human cells are also 
capable  of producing them and their production acts as a means of communication between both 
cells and tissue (81). Cytokines may be classified into the following categories: interleukin (IL) (1-
15), growth factors, colony-stimulating factors, interferons (IFN) (α, β and γ), tumor necrosis 
factor (TNF) and chemokines. These cytokines can have either pro or anti-inflammatory activity 
and immunosuppressive activity, depending on the microenvironments (81).  
Glioma-associated microglia and macrophages (GAM) and myeloid-derived suppressor cells 
(MDSC) condition the glioma microenvironment to generate an immunosuppressed niche for 
tumour expansion (82). Glioma cells recruit GAM and MDSC to the tumour site and block their 
maturation. Glioma cell-derived factors subsequently skew these cells towards an 
immunosuppressive, tumour-promoting phenotype. Finally, GAM and MDSC enhance immune 
suppression in the glioma microenvironment and promote tumor growth, invasiveness, and 
neovascularization (82). The local and distant cross-talk between glioma cells and GAM and 
MDSC is regulated by a plethora of soluble proteins and cell surface-bound factors. 
The population of GAM that is found in glioma is believed to predominantly contribute to the 
induction of an immunosuppressive glioma microenvironment (82)(Figure
1. GAM are recruited to the tumor via different glioma-derived factors that subsequently 
contribute to a switch from a tumor-suppressive M1 to a tumor-promoting M2 phenotype. 
This recruitment is mediated through various glioma-derived factors including 
chemokines, cytokines and matrix proteins. CSF-1 (M-CSF), TNF, VEGF, and GM-CSF  
have previously been reported to guide the recruitment and migration of GAMs into the 
glioma environment.  Moreover, it has been suggested that such glioma stem-like cells 
recruit circulating monocytes via CSF-1 and the chemokine CCL2, and that this process 
is more effective than recruitment by regular glioma cells. Activated M1 GAM are 
stimulated by LPS and IFNγ and are able to effectively promote an anti-tumor immune 
response. M1 GAM produce pro-inflammatory mediators, phagocytes’ tumor cells, 
present tumor antigens to immune cells, and stimulate them to trigger an antigen-specific 
T cell response. Glioma cells actively secrete factors including IL-4, IL-6, IL-10, MIF, 
 1.6.3). They directly 
and indirectly interact with glioma cells in various ways: 
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TGF-β1
2. M2 GAM mediate immune suppression in the glioma microenvironment through 
secretion of immunosuppressive factors including IL-6, IL-10, and TGF-β1 and 
interaction with other immune cells. IL-10 release has been found to be regulated by 
STAT3, and mediates a range of immunosuppressive mechanisms. These include 
amongst others the inhibition of an anti-tumor response by the down-regulation of HLA-
DR expression on monocytes, and their decreased production of inflammatory cytokines. 
GAM in turn promote immune suppression via the induction of T-cell anergy and 
apoptosis, expansion of Treg cells, inhibition of T-cell activation and proliferation and 
decreasing the activity of Lymphokine Activated Killer (LAK) cells, Natural Killer (NK) 
cells and Cytotoxic T lymphocyte (CTL) (83). 
, and PGE-2 that skew the phenotype of GAMs to a M2 phenotype. Acquisition 
of the M2 phenotype is accompanied by an incompetence to induce an anti-tumor T-cell 
response and by immunosuppressive features. 
3. M2 GAMs produce factors that stimulate glioma growth, neovascularization, and       
invasiveness. An important example is represented by the glioma-induced production of 
matrix metalloproteases (MMP), especially MMP-2 and MMP-9. MMP-2 is produced by 
both glioma cells and microglia, and is believed to promote matrix remodeling and to 
manipulate glioma cells in various other ways, by affecting glioma cell metabolism, 
receptor turnover and apoptosis resistance. MMP-9, the second key MMP in glioma 
progression, is also secreted by microglia and glioma cells. The expression of MMP-9 
can be triggered by multiple factors derived from GAM. 
Multiple lines of evidence suggest that immunosuppressive cytokines expressed by GAM 
might also play an important role in the promotion of glioma proliferation and motility. 
IL-6, IL-10, and TGF-β have all been reported as potent inducers of glioma invasiveness. 
Beside its effects on immune suppression, TGF-β1 has been demonstrated to enhance 
MMP-9 expression in glioma stem-like cells and consequently promote their 
invasiveness. Moreover, TGFβ1 can induce up-regulation of VEGF in glioma cells and 
thus potentially contribute to glioma angiogenesis. In addition, GAM stimulate glioma 
proliferation and angiogenesis by various other mechanisms including the production of 
EGF and, again, VEGF. 
 
                                                            
1 Transforming growth factor β (TGF-β) is a family of pleiotropic cytokines consisting of three members, TGF-β1, 
TGF-β2, and TGF-β3. It activates a serine/threonine-kinase receptor. TGF-β proteins as well as their functional 
receptors are expressed in glioblastoma and anaplastic astrocytoma but are just detectable in low-grade gliomas and 
normal brain. 
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Figure 1.6.3. M1 and M2 GAMs. Schematic representation of the two different GAM subtypes 
with opposing immunological functions (82). 
 
Myeloid Derived Suppressor Cells (MDSC) are known to exert remarkable immunosuppressive 
activities in cancer (82). MDSC mediate immune suppression by depleting essential nutrients for 
lymphocytes, hampering their trafficking and viability, producing reactive nitrogen species and 
ROS, as well as activating and inducing expansion of Treg cells. IL-6,M-CSF, COX-2/PGE-2 
(Cyclooxygenase 2 / prostaglandin E2), IL-1β, TNF-α, and VEGF were previously shown to 
stimulate the differentiation of normal human peripheral blood mononuclear cells into MDSCs in 
vitro. As gliomas are known to over-express these factors, it is likely that they also induce the 
generation of MDSC in vivo. 
 
In the TME glioma cells have been found to express multiple factors such as IL-1β , IL-6 and IL-
8 (83), (84). IL-1β may directly stimulate glioma cell proliferation and induce the secretion of other 
cytokines like IL-6 and IL-8 by an autocrine loop (85). IL-1β, IL-6 and IL-8 share the capacity to 
induce the expression and secretion of MMP-2, MMP-9 in normal and tumor cells. Thus, these 
factors may contribute to invasion of glioma cells through the induction of matrix degrading 
proteinases (86), (87), (88). Besides, IL-1β can enhance gene expression of TGF-β2. Increased 
transcription of TGF-β2 can lead to suppression of anti-glioma responses by inhibiting the 
proliferation of lymphocytes, reducing immune cell activation, blocking antitumor activity, and 
inhibiting antigen presentation (7). 
The expression of these cytokines is up-regulated by Nuclear Factor-κB (NFκB), an inducible 
transcription factor that plays a key role in regulating the expression of numerous immune and 
inflammatory response genes. NFκB family consists of five members and the predominant form 
of NFκB is a dimer composed of p65 and p50 proteins. It is normally expressed in an inactive 
state in the cytoplasm where it is bound by its inhibitor protein family IκB. NFκB activation 
involves IκB phosphorylation and proteasome–mediated degradation leading to NFκB release. 
Once released, NFκB translocates to the nucleus where it becomes phosphorylated, binds to 
DNA and induces the expression of genes involved in inflammation such as IL-8 and IL-6, as 
well as anti-apoptotic genes including cIAP2, Bcl-2 and Bcl-xL (89). Several studies have 
demonstrated that the activity of NFκB is elevated in many cancers, including GBM (89), (90). A 
work conducted in 2004 evaluated immunohistochemical changes of this transcription factor in 
human brain glioma and human brain metastatic carcinoma (HBMC) and the role of NFκB in the 
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biological behavior of the tumors (90). Normal brain tissues had only trace expression of NFκB, 
whereas all tumor tissues examined expressed it. The level of NFκB in HGG, HBMC and 
recurrent glioma tissues was considerably higher than that in LGG tissues. Briefly, NFκB 
expression is associated with the malignant progression, invasion and angiogenesis of HBG and 
HBMC, and it may play a crucial role in the recurrence of glioma. 
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2. AIM OF THE STUDY 
 
Gliomas are primary central nervous system tumors that arise most frequently in the cerebral 
hemispheres of adults (8). 
These tumors are graded on a WHO consensus-derived scale of I to IV according to their degree 
of malignancy as judged by various histological features accompanied by genetic alterations (91). 
WHO grade I and grade II gliomas are summarized as low grade glioma (LGG) and WHO grade 
III and grade IV are summarized as high grade glioma (HGG). While HGG are characterized by 
a poor prognosis (e.g. grade IV gliomas have a median survival of 12-15 months), LGG are 
usually well differentiated, slow growingand have a better prognosis (9) (11). 
However, although grade I LGG are characterized by an excellent prognosis, grade II LGG grow 
slowly but ineluctably evolve to anaplasia in turn leading to neurological disability and 
ultimately to death, within 5-10 years (27). Additionally, in grade II LGG, the natural course of the 
disease varies considerably and histological analyses, even when combined with newly identified 
molecular markers, partially fail in predicting the clinical evolution of the lesions (29). Therefore, 
the management of patients with grade 2 LGG is a challenge, because: 1. There are not definitive 
criteria to classify a lesion as at high risk or low risk to relapse and/or progression and 2. Current 
possible adjuvant therapies can produce or contribute to chronic neuro-cognitive function 
impairment, particularly radiotherapy. Therefore, to profoundly impact the outcome of glioma 
patients, new drugs and better prognostic/predictive factors are strongly required (92). In this 
regard, great interest is now focused on the tumor microenvironment (TME) considered to be 
crucial for tumor progression and metastasis (93).  
In collaboration with the Neurosurgery Department of the Azienda Ospedaliero-Universitaria of 
Udine, we have recently isolated from both HGG and LGG a population of stem cells devoid of 
tumorigenic features but characterized by tumor-supporting activities, being able, through the 
release of exosomes, to increase the biological aggressiveness of glioma-initiating cells. 
Importantly, the in vitro features of these cells, named GASC (Glioma-Associated Stem Cells), 
were the strongest predictor of LGG patients’ overall survival and malignant progression free 
survival outperforming the state-of-the-art prognostic factors, including chromosome 1p-19q co-
deletion, MGMT-promoter methylation status and IDH1-IDH2 gene mutation8. This supports the 
notion that GASC could represent a patient-based approach and could provide a groundbreaking 
method to identify novel prognostic/predictive markers and to exploit innovative therapeutic 
strategies aimed at targeting the tumor stroma. 
However, cellular culture approaches are not frequently used in pathology department whereas  
ancillary studies such immunohistochemistry and molecular biology remain the gold standard for 
the diagnosis of glioma. Since immunohistochemistry is less expensive and widely available, it is 
often used in favor of other methods. For this reason this thesis aims at analyzing the gene 
expression profile of GASCs derived from LGG to identify putative novel prognostic factors  
that have been finally validated in a case study including 175 formalin-fixed paraffin-embedded 
LGG. Specifically: 
1. GASC from LGG characterized by two different prognosis were cultured and analyzed: 
GASC from LGG without clinical evidence of anaplastic progression at 7 year from 
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diagnosis (LGG-good) and GASC from LGG characterized by anaplastic transformation 
within 4 years (LGG-bad) 
2. Taking advantage of next generation sequencing and bioinformatics techniques, the gene 
expression profile of GASCs isolated from LGG-good and LGG-bad were compared and 
molecules (“upstream regulators”) considered to be responsible for the differences in the 
gene signatures of the two groups, the so called “upstream regulators”, were identified; 
3. The expression of putative novel markers obtained by analyzing GASC, was assessed by 
immunohistochemistry, in LGG and HGG; 
4. The prognostic value of the novel biomarkers was finally evaluated in a case study 
including 175 LGG well characterized from a clinical and pathological point of view and 
with an updated follow-up. 
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3. METHODS AND MATERIALS 
 
3.1 SAMPLE STUDY 
 
Human glioma samples were collected by the Department of Neurosurgery of the Azienda 
Ospedaliero-Universitaria of  Udine directed by Dr. Miran Skrap. Informed consents were 
obtained from patients and all clinical investigations were conducted according to the principles 
expressed in the Declaration of Helsinki. The independent ethic committee of the Azienda 
Ospedaliero-Universitaria of Udine and the regional ethic committee approved the research 
(Consent 102 / 2011 / Sper and Consent 196 / 2014 / Em). 
After glioma resection, tumor fragments (with a weight ranging from 20mg and 2g) were sent to 
the Department of Pathology of Udine. 
Samples were divided in three parts: part of the samples were immediately snap frozen and 
stored at -80°C, part formalin-fixed paraffin-embedded (FFPE), and part freshly used for GASC 
isolation (79). 
Eligibility criteria included written informed consent and availability of follow-up data. 
Extensive surgical resection was done at diagnosis and radio- and/or chemotherapy was 
administered in case of tumor progression or malignant transformation. Regarding the selection 
of patients for the study of the expression profile of GASC, we considered LGG with a good 
prognosis, patients without malignant transformation after at least 7 years from the first surgery 
and, LGG with a poor prognosis, those patients who died of neoplasm or of malignant 
transformation within 48 months from the first surgical treatment. Patients’ characteristics are 
shown in tables 4.1 and 4.2. As regards cases included in the comparison between HGG and 
LGG, patients’ characteristics are shown in tables 4.5 and 4.6  . 
 
3.2  GLIOMA HISTOLOGICAL CHARACTERIZATION 
 
The histological characterization of gliomas was conducted in collaboration with the Department 
of Pathology of Udine within a transboundary programme between Italy and Slovenia named: 
“Identificazione di nuovi marcatori di cellule staminali tumorali a scopo diagnostico e 
terapeutico”. 
Tumors were histologically reviewed by two expert neuropathologist according to the WHO 
classification of tumors of the central nervous system (9). Mitotic index was evaluated on 
Hematoxylin/Eosin stained sections by the number of mitosis in 10 high-power fields. 
Immunohistochemistry was performed on 4 μm-thick formalin-fixed paraffin-embedded slides. 
Sections were deparaffinized and pretreated for heat induced epitope retrieval using EnVision™ 
FLEX citrate buffer, pH 6.1, in PT Link (Dako) then placed in an automated immunostainer, 
Autostainer Link 48, (Dako) and incubated for 30 minutes at room temperature with the 
following mouse anti-human monoclonal antibodies: Ki-67 (1:200, clone Mib-1, Dako), GFAP 
(1:400, clone 6F2, (Dako), EGFR (1:50, clone 31G7, Zymed Laboratories Inc.), p53 (1:200, 
clone D07 Dako) and IDH1R132H (1:150, clone H09, Dianova), ATRX (1:200, rabbit polyclonal, 
Sigma). Primary antibodies were detected using EnVision™ FLEX system (Dako). Ki-67 was 
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scored as percentage of positive nuclei. All other markers were qualitatively evaluated as 
negative or positive. All negative IDH1R132H cases were then amplified for IDH1 and IDH2 
gene status assessment.  
FISH analysis for 1p36 and 19q13 deletions was performed on 4 μm-thick formalin-fixed 
paraffin-embedded sections using dual-color 1p36/1q25 and 19q13/19p13 probes (Vysis 
1p36/1q25 and 19q13/19p13 FISH Probe Kit, Abbott Molecular). Briefly, sections were 
deparaffinized and pretreated with 1M sodium thiocyanate solution at 80°C for 30 minutes. After 
washing in 2x SSC buffer, slides were immersed in a protease solution at 37°C for 15-30 
minutes, then washed twice in 0.4X SSC/0.3% NP-40 buffer and then air-dried. Probes and 
target were simultaneously denatured at 73°C for 5 minutes and hybridized at 37°C for 18-20 
hours. Slides were then immersed in 2xSSC-0.3% NP-40 for 5 minutes at 73°C and, finally, 
counterstained with DAPI. For each case 50-100 non-overlapping nuclei were analyzed and 1p 
or 19q deletion status was defined if the 1p36/1q25 or 19q13/19p13 signal ratio was lower than 
0.80, respectively. Co-deletion status was defined if both 1p and 19q ratio were lower than 0.80. 
IDH gene status and MGMT promoter methylation were assessed on DNA extracted from 
formalin-fixed paraffin-embedded tissue with QIAmp DNA mini kit (Qiagen). DNA 
concentration was estimated with NanoDrop2000c spectrophotometer (Thermoscientific). IDH1 
and IDH2 genes regions spanning codon 132 (IDH1) and codon 172 (IDH2) were amplified on 
Rotor-Gene 6000 (Corbett) and pyrosequencing of PCR products were performed on Pyromark 
Q96 ID (Qiagen) as previously reported (94) and analyzed with Pyromark ID 1.0 (Biotage AB) 
software. After DNA bisulfite conversion with EpiTect Bisulfite Kit (Qiagen), methylation levels 
of the MGMT promoter in position 17-39 of exon 1 were investigated, by PyroMark Q96 CpG 
MGMT (Qiagen) according to manufacturers’ instructions. 
 
3.3  GASC ISOLATION AND CULTURE 
 
Cells from glioma were isolated and cultured applying, with minor modifications, a protocol 
optimized for culturing multipotent adult stem cells from normal (95), (96) and neoplastic human 
tissues (97). Briefly, glioma fragments were first disaggregated mechanically with scalpels and 
then enzimatically dissociated, in a 0.0125% Collagenase type II solution (Worthington) in 
Joklik modified Eagle’s Medium (Sigma-Aldrich), for 5 minutes at 37°C. Collagenase activity 
was stopped by the addition of 0.1% bovine serum albumin (Sigma-Aldrich) solution in Joklik 
modified Eagle’s Medium (Sigma-Aldrich). Cell suspension was centrifuged at 500g for 10 
minutes and filtered through a sieve (BD Falcon) in order to select a population less than 40 μm 
in diameter. 2.0x106 freshly isolated human cells were plated onto 100 mm in diameter, human 
fibronectin (Sigma-Aldrich)-coated dishes (BD Falcon), in an expansion medium composed as 
follows: 60% low glucose DMEM (Invitrogen), 40% MCDB-201, 1mg/mL linoleic acid-BSA, 
10-9 M dexamethasone, 10-4 M ascorbic acid-2 phosphate, 1X insulin-transferrin-sodium selenite 
(all from Sigma-Aldrich), 2% fetal bovine serum (Stemcell Technologies Inc.), 10 ng/ml human 
PDGF-BB, 10 ng/ml human EGF (both from Peprotech). Cells were cultured in an incubator at 
37°C, 5%O2/5%CO2. Medium was replaced with fresh one every 4 days. Once cells reached 70-
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80% of confluence, they were detached with TrypLE Express (Invitrogen) and re-plated at a 
density of 1-2x103/cm2.  
 
3.4  SURFACE IMMUNOPHENOTYPE CHARACTERIZATION  
 
Cells populations were detached with 0.25% trypsin-EDTA (Sigma-Aldrich) and then incubated 
with either properly conjugated primary antibodies: CD11b, CD13, CD29, CD45, CD49a, 
CD49b, CD49d, CD90, CD73, CD44, CD59, CD45, HLA-DR, CD117, CD271, CD34, CD325 
(Becton Dickinson) CD105, CD66e (Serotec), CD133 (Miltenyi Biotec), E-Cadherin (Santa Cruz 
Biotechnology), ABCG-2 (Chemicon International), or with an unconjugated primary antibody: 
N-cadherin (Sigma-Aldrich). Unconjugated antibody was revealed using PE or FITC conjugated 
secondary antibodies (Dako). Properly conjugated isotype matched antibodies were used as a 
negative control. The analysis was performed either by FACS-Calibur (Becton Dickinson) or by 
CyAn (Dako). 
 
3.5  IMMUNOFLUORESCENCE ASSAY ON GASC 
 
Cells cultured either in expansion or in differentiation medium were fixed in 4% buffered 
paraformaldehyde for 20 minutes at room temperature (RT). For intracellular stainings, fixed 
cells were permeabilized for 10 minutes at RT with 0.1% Triton X-100 (Sigma-Aldrich) before 
exposing them to primary antibodies. In order to block unspecific binding of the primary 
antibodies, cells were incubated with 10% donkey serum in PBS for 30 min. Primary antibody 
incubation was performed over-night at 4°C to detect: Oct-4 (Abcam, 1:150); Sox-2 (Chemicon 
International, 1:150); Nanog ( Abcam, 1:150); Nestin (Millipore, 1:100); GFAP (Dako, 1:50); 
Vimentin (Dako, 1:500). To detect primary antibodies, A488- and A555- labeled secondary 
antibodies, diluted 1:800, were employed (Molecular Probe, Invitrogen). Finally, Vectashield 
(Vector Laboratories Inc.) added with 0.1 μg/ml DAPI (Sigma-Aldrich) was used as mounting 
medium. Epifluorescence and phase contrast images were obtained utilizing a live cell imaging 
dedicated system consisting of a Leica DMI 6000B microscope connected to a Leica DFC350FX 
camera (Leica Microsystems) and equipped with a 63X oil immersion objective (numerical 
aperture: 1.40) or a 40X oil immersion objective (numerical aperture: 1.25). Adobe Photoshop 
software was utilized to compose, overlay the images and to adjust contrast (Adobe). There were 
analyzed almost 300 cells for quantification of the protein expression.  
 
3.6  SOFT AGAR ASSAY 
 
To evaluate the ability of GASC to grow in an anchorage-independent way, 3x105 cells at the 
third passage in culture, were plated in a 0.25% soft agar solution in 35-mm plates containing a 
basal layer of 1% agarose. After 4 weeks, the total number of formed colonies were counted 
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under a phase contrast microscope (Leica DM IL, Leica Microsystems) equipped with a 10X 
objective (numerical aperture: 0.25). Assays were performed in triplicate. 
 
3.7  RNA EXTRACTION AND SEQUENCING FROM HUMAN 
GASC 
 
Total RNA was extracted from GASC using the TRIzol Reagent (Invitrogen) following the 
company’s instructions and then it was suspended in nuclease-free water. 
For each sample it was extracted at least 4 µg (Nanodrop) of RNA according to criteria 
established from the Institute of Applied Genomics (IGA, Udine, Italy) for the sequencing; the 
criteria were: ratio 260/280 > 1.8; RNA Integrity Number (RIN)> 8 (Agilent Bioanalyzer 2100); 
minimum RNA concentration of 40ng/µL. 
Transcriptome GASC sequencing was performed by IGA using the Illumina mRNASeq Sample 
Prep kit v2.0. The poly-A mRNA was fragmented 3 minutes at 94°C and every purification step 
was performed by using 1X Agencourt AMPure XP beads.  
Single read sequencing was performed on the HiSeq2000 (Illumina) generating 50-base reads. 
The platform permitted an analysis of 30 million sequence/sample.  
3 GASC lines from glioma with a good prognosis and 3 GASC lines from glioma with a bad 
prognosis were sequenced.  
Bioinformatic analysis was performed by Laboratorio Nazionale del Consorzio Interuniversitario 
per le Biotecnologie (LNCIB) which verified data availability removing linker sequence, 
marking sequence errors and mapping on the genome reference sequence (hg19) (preprocessing 
and mapping phases) (98). These preliminary phases showed that obtained data were of good 
quality and that over 90% of reads were available for the following analysis phases. It was 
provided a list of genes that were differently expressed between the two GASC groups. The 
results supplied the differential expression levels and the statistical power of the difference (p 
and q value). 
The miRNA list was analyzed by using Upstream regulators prediction instrument included in 
Ingenuity Pathway Analysis software. This analysis identifies regulators, relationships, 
mechanisms, functions, and pathways relevant to changes observed in cells studied. The analyses 
provided tables, which show molecules able to modify the transcriptional program observed. The 
prediction score (z score), the overlay p-value and the genes regulated list included in the 
analyzed dataset were defined for each molecule.  
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3.8   IMMUNOHISTOCHEMICAL VALUATION OF UPSTREAM 
REGULATORS 
 
To evaluate a possible difference in the expression of three upstream regulators (IL-1β, IL-6 and 
p65/NFκB) betweenLGG (n=5) and HGG (n=5), an immunohistochemical assay on sections, 
obtained from formalin-fixed paraffin-embedded, glioma tissueshas been optimized. 
4μm-thick sections were deparaffinized and pretreated for heat induced epitope retrieval using 
EnVision™ FLEX Target Retrieval Solution, High pH (IL-1β) or EnVision™ FLEX Target 
Retrieval Solution, Low pH (IL6, p65/NFκB). 
Endogenous peroxidase was blocked with a solution of hydrogen peroxide (3,5% H2O2 in 
distilled H2O), for 10 minutes at room temperature. Slides were then incubated with the 
following primary antibodies: IL-1β (Abcam, clone 3E1, 1:50, overnight); IL6 (Abcam, rabbit 
polyclonal, 1:250, overnight); P65/NFκB (Abcam, rabbit polyclonal, 1:500, 60 minutes at room 
temperature). Primary antibodies were detected using Dako EnVision + Dual Link System-HRP 
(DAB+) system, according to company’s instructions. Slides were counterstained with Gill’s 
Hematoxylin, dehydrated and mounted with Eukitt. 
Positive controls were breast cancer- (IL-6 and p65/NFκB) and endometrial cancer- (IL-1β) 
tissues, while negative controls were obtained by omitting the primary antibody. 
Slides were scanned at 40x magnification by using Aperio CS2 digital scanner (Leica 
Biosystems).  
Images were then analyzed by Image J program quantifying optic mean density of each sample 
for area’s unit.  
 
3.9  TISSUE MICROARRAY (TMA) CONSTRUCTION 
 
14 tissue microarrays (TMA) including 163 glioma samples (161 LGG and 2 HGG) were built. 
Glioma samples are well characterized both histopathologically and clinically and up-to-date 
clinical follow-up of the patients is available. 
From formalin-fixed paraffin-embedded glioma’s blocks, 4μm-thick sections were obtained  and 
stained by Hematoxylin/Eosin (H&E). An expert neuropathologist on the basis of specific 
criteria (i.e. atypia, differentiation grade, cellular and nuclear polymorphism, microvascular 
proliferation, necrosis, heterogeneity, as well as hypercellularity) located and labeled in the H&E 
sections of each glioma sample, three areas representative of the glioma.  
The TMA construction was then performed by using the GALILEO CK4500 instrument 
(Integrated System Engineering). 
The areas of interest, previously marked, were matched to its approximate position in the donor 
block. A core of wax (1 mm diameter) was removed from the recipient block using a stylet 
before the donor core was taken and placed in this hole using a second stylet (Figure 3.1). Three 
cores were taken for each sample and the TMA was created with multiple different cases.  
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Figure 3.1. Steps of TMA construction using a manual tissue microarrayer. For details see paragraph 
2.9 (99). 
 
 
Orientation of the cores was guaranteed by using two non-glioma tissues (i.e. murine tissue and 
human placenta) as point of reference (Figure
 
 3.2). 
 
Figure
 
 3.2. TMA block obtained after construction. 
 
In TMA, samples were grouped on the basis of histopathology. 
 
 
 
Orientation cores 
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3.10 TMA PROCESSING 
 
4μm-thick sections were obtained from TMA blocks and treated for immunohistochemical 
assays as previously described in paragraph 3.8.  
 
3.11  TMA ANALYSIS 
 
TMA slides were scanned at 40x magnification by using Aperio CS2 digital scanner (Leica 
Biosystems). Il-6 images were then analyzed by Image J program quantifying optic mean density 
of each sample for area’s unit. For IL1β and p65, characterized by nuclear and cytoplasmic 
localization, images were evaluated by three independent observers that semiquantitatively 
scored nuclear and cytoplasm positivity. In the first case, the following parameters were 
quantified: fraction of positive nuclei; nuclear staining intensity (from 1 to 4); nuclear score 
(product of the fraction of positive nuclei and nuclear intensity). The cytoplasm score (an 
arbitrary number between zero and three) has been assigned on the basis of the staining intensity. 
 
3.12 STATISTICAL ANALYSIS 
 
As regards GASC analysis (surface immunophenotype, immunofluorescence and soft agar 
growth), characteristics of patients and valuation of IL-1β, IL-6 and p65/NFκB at tissue level, 
data are expressed as mean ± standard deviation or as median and interquartile range, based on 
Gaussian distribution. 
The comparison between two groups was performed by using t Student test or Mann Whitney 
test, as appropriate. A p value < 0.05 was considered significant.  
As regards clinical and histological parameters and TMA analysis of IL-1β, IL-6 and p65/NFκB 
expression, in order to define a prognostic value, Overall Survival (OS), Progression-free 
Survival (PFS) and Malignant Progression-free Survival (MPFS) were described using the 
Kaplan-Meier method. In particular, OS was defined as time between initial surgery and death; 
PFS was defined as time between initial surgery and demonstration of unequivocal increase in 
tumor size on follow-up imaging, malignant progression, and/or death; MPFS was defined as 
time between initial surgery and demonstration of gadolinium enhancement on follow-up 
imaging and/or higher-grade tumor on subsequent biopsy or death. Analysis of survival was 
done using Cox proportional hazard model.  
At the univariate analysis, age, sex, extent of tumor resection, histotype, p53 expression, IDH1/2 
mutation presence, 1p/19q co-deletion, MGMT promoter methylation status and IL-1β, IL-6 and 
p65/NFκB expression were variables considered as possible prognostic factors. 
At the multivariate analysis, covariates which presented a p <0.010 at the univariate analysis 
were selected. Variables had to present a p <0.05 to be considered in the stepwise model. Results 
are presented as hazard ratio (HR) and confidence interval at 95% (CI 95%). 
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4. RESULTS 
4.1 CHOICE AND CHARACTERIZATION OF GASC FROM LGG 
 
In this study we used 3 GASC lines obtained from 3 patients without malignant transformation 
after more than 7 years from the first surgery (LGG-good) and 3 GASC lines obtained from 3 
patients who died of neoplasm or underwent malignant transformation within 48 months from 
the first surgery (LGG-bad). Table 4.1 and 4.2 illustrate clinical-pathological features of patients 
included in the study. 
 
ID Sex 
Age at 
diagnosis 
Histotype  Ki67 (%) p53 
1p 
deletion 
19q 
deletion 
1p/19q 
codel 
IDH1 IDH2 
IDH1/ID
H2 
MGMT 
Alive/Dea
d  
OS 
(months) 
PFS 
(months) 
MPFS 
(months) 
1 M 29 
Diffuse 
astrocytom
a 
7 1 0 1 0 1 0 1 1 A 111 111 111 
13 F 39 
Oligoastroc
ytoma 
3 1 1 1 1 1 0 1 1 A 103 60 103 
27 F 41 
Diffuse 
astrocytom
a 
4 1 0 0 0 1 0 1 1 A 98 70 95 
                               36±6                     5±2                                                                                                                        104±7   80±27   103±8 
Table 4.1. Clinical-pathological features of LGG-good patients included in the study. 
Table reports data about histological analysis, common molecular features and patient prognosis, 
referred to 3 LGG with a good prognosis. F = female; M= male; p53 = p53 mutation; IDH1 = mutation of 
IDH1 gene; IDH2 = mutation of IDH2 gene; IDH1/IDH2: mutation of either IDH1 or IDH2 gene; MGMT = 
methylation of MGMT promoter; 0 = absent; 1 = present; D = dead; A = alive; n.d. = not determined. OS 
= overall survival; PFS = progression free survival; MPFS = malignant progression free survival. 
 
 
ID Sex 
Age at 
diagnosis 
Histotype Ki67 (%) p53 
1p 
deletion 
19q 
deletion 
1p/19q 
codel 
IDH1 IDH2 
IDH1/ID
H2 
MGMT 
Alive/Dea
d 
OS 
(months) 
PFS 
(months) 
MPFS 
(months) 
2 M 63 
Oligoastroc
ytoma 
8 0 1 1 1 1 0 1 1 D 59 48 48 
25 M 54 
Diffuse 
astrocytom
a 
20 0 0 0 0 0 0 0 0 D 26 12 12 
32 F 47 
Oligoastroc
ytoma 
4 1 0 0 0 1 0 1 1 D 25 18 18 
                             55±8                       11±8                                                                                                                                               37±19    16±19  26±19     
 
Table 4.2. Clinical-pathological features of LGG-bad patients included in the study. 
Table reports data about histological analysis, common molecular features and patient prognosis, 
referred to 3 LGG with a good prognosis. F = female; M= male; p53 = p53 mutation; IDH1 = mutation of 
IDH1 gene; IDH2 = mutation of IDH2 gene; IDH1/IDH2: mutation of either IDH1 or IDH2 gene; MGMT = 
methylation of MGMT promoter; 0 = absent; 1 = present; D = dead; A = alive; n.d. = not determined. OS 
= overall survival; PFS = progression free survival; MPFS = malignant progression free survival. 
 
GASC lines were obtained according to the protocol optimized in our laboratory8 and 
cryopreserved in liquid nitrogen. These lines were thawed and expanded in vitro according to our 
protocol.  
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To establish whether GASC, even after seven years from collection, still possessed features of 
stem cells with tumor-supporting ability, we verified in thawed and expanded in vitro GASC: 
1. The expression of an undifferentiated phenotype; 
2. The ability to grow in anchorage-independent conditions (soft agar assay). 
 
4.1.1 LGG GASC WERE CHARACTERIZED BY AN 
UNDIFFERENTIATED PHENOTYPE 
 
Flow-cytometry analysis of the surface immunophenotype confirmed that GASC shared a 
mesenchymal phenotype (Figure
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.1), as they were markedly positive for antigens like CD90, 
CD105 and CD73 and they were negative for hematopoietic markers like CD45 and CD38.  
 
 
    A 
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  B 
 
Figure 4.1. Surface immunophenotype of GASC included in the study. 
A: Representative surface immunophenotype of LGG-GASC line. 
Histograms overlays show isotype control IgG staining profile (red histograms) versus specific antibody 
staining profile (green histograms). 
B: Table comparing GASC-LGG-GOOD versus GASC-LGG-BAD expression of the assayed surface markers 
(mean ± SD) 
 
In order to test whether GASC were characterized by an undifferentiated state, we tested by 
immunofluorescence the expression of the pluripotent state-specific transcription factors Oct-4, 
NANOG and Sox-2. The Figure 4.2 shows that most of the cultured cells expressed Oct-4, 
NANOG and Sox-2, confirming that cultured GASC maintained an undifferentiated 
transcriptional phenotype. 
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Figure 4.2. Pluripotent state-specific transcription factors expression. 
A-C: representative images of Oct-4 expression (green fluorescence, A), NANOG expression (red 
fluorescence, B), and Sox-2 expression (yellow fluorescence, C) in LGG-GASC. Nuclei are depicted by the 
blue fluorescence of DAPI staining. D:Histograms comparing the expression of Oct4, NANOG and Sox-2 
in GASC obtained, respectively, in LGG-GOOD and LGG-BAD. Data are expressed as mean ± SD. 
 
GASC lines were subsequently tested for the cytoplasmic expression of proteins characterizing 
undifferentiated neural cells, i.e. vimentin and nestin. Since tumors examined are of glial origin, 
it was also tested the expression of GFAP, an intermediate filament expressed in several glial 
cells. As shown in Figure 4.3, a large number of GASC expressed both nestin, an intermediate 
filament characterizing primitive cells, and vimentin, an intermediate filament characterizing not 
only mesenchymal cells but also several cell types in the early phases of differentiation; 
conversely, GFAP was present and organized in filaments only in a minority of GASC (Figure 
4.3). 
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Figure 4.3. Expression of cytoplasmic filaments characterizing an undifferentiated state. 
A, B: representative images of the expression in GASC of vimentin (green fluorescence, A), nestin (red 
fluorescence, B) and GFAP (yellow fluorescence, C). Nuclei are depicted by the blue fluorescence of DAPI 
staining. D: histograms depict as mean ± SD the fraction of cells expressing the tested intermediate 
filaments in both GASC-LGG-BAD and GASC-LGG-GOOD. 
 
In conclusion, GASC lines presented a surface immunophenotype, a transcriptional asset and an 
intermediate filament expression profile consistent with an undifferentiated phenotype. 
 
4.1.2 LGG GASC RETAINED ABERRANT GROWTH PROPERTIES 
 
Once it was proven that thawed GASC lines continue to present phenotypic stem cell features, 
we tested whether they retained also the typical property of tumor supporting cells, i.e. an 
anchorage-independent growth in a semisolid medium. With this purpose, GASC were cultured 
in soft agar (0,25% agar concentration). All GASC lines examined displayed the ability to grow 
in an anchorage-independent way, without significant statistical differences (Figure 4.4).  
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Figure
4.2 TRANSCRIPTOMIC ANALYSIS OF GASC 
 4.4. GASC anchorage-independent growth.  
A: phase-contrast image (10x) of colonies grown for 4 weeks in a semisolid medium. 
B: quantification of the absolute number of colonies >100µm in diameter formed after 4 weeks (data 
are presented as mean ± SD). 
 
 
After checking that thawed GASC retained phenotypic features of stem cells with tumor-
supporting ability, cells were expanded and RNA was extracted and analyzed by using deep-
sequencing in collaboration with the Applied Genomic Institute (IGA). 
82 genes (Table 4.3) resulted to be differentially expressed between GASC obtained from LGG 
characterized by a good prognosis (q1) and those obtained from LGG characterized by a poor 
prognosis (q2), respectively. 
Only one of the 82 genes, NPTX1, resulted to be over expressed in GASC from LGG with a 
good prognosis, meanwhile all the other genes resulted to be up regulated in GASC from LGG 
with a bad prognosis.  
As a whole, the gene expression profile of GASC from LGG with a bad prognosis was 
characterized by elements typical of an inflammatory response and, in part, of the so-called 
senescence-associated secretory phenotype (SASP).  
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Table 4.3. Genes differentially expressed between GASC isolated from LGG characterized by a good 
prognosis and those isolated by LGG with a poor prognosis (bad), respectively. 
  Gene involved in inflammatory response 
  Gene involved in SASP 
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Afterwards, the transcriptional program of GASC was verified at LNCIB (in collaboration with 
Doctor. S. Piazza and Doctor. Y. Ciani) by using Upstream regulators analysis (included in 
Ingenuity Pathway Analysis) and upstream regulators potentially responsible of the differences 
in the transcriptional profile between GASC isolated from LGG with different prognosis were 
identified (Table 4.3). 
 
 
 
Table 4.4. Upstream regulators analysis (included in Ingenuity Pathway Analysis). 
Table reports a selection of molecules involved in the differences in the transcriptional program 
observed. z-score of prediction, p-value of overlap and the list of genes regulated in the analyzed 
dataset are shown. 
 
The upstream regulators, which have the higher probability (z-score) to activate a molecular 
signature characterizing GASC of gliomas with a bad prognosis, were cytokine and 
transcriptional regulator of the inflammatory response. In particular, we decided to focus our 
attention on IL-1β, IL-6 and p65/NFκB (RELA) because they represent three different 
inflammatory pathways involved in the progression of glioblastoma (100). 
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4.3 IMMUNOHYSTOCHEMICAL EVALUATION OF THE 
EXPRESSION OF UPSTREAM REGULATORS  AT TISSUE LEVEL 
 
 
In order to establish whether selected upstream regulators were expressed at tissue level, 5 LGG 
tissues were selected. Since we hypothesized that the “upstream regulators” could be related to 
an increased aggressiveness, 5 HGG were included as well. Tables 4.5 and 4.6 report features of 
glioma samples selected for the assessment of IL-1β, IL-6 and p65/NFκB expression. 
 
ID Sex 
Age at 
diagnosis 
Histotype  
Ki67 
(%) 
p53 
1p 
deletion 
19q 
deletion 
1p/19q 
codel 
IDH1 IDH2 IDH1/IDH2 MGMT Dead/Alive  
OS 
(months) 
13 F 40 Oligoastrocytoma 4 1 1 1 1 1 0 1 1 A 103 
25 M 54 
Diffuse 
astrocytoma 
20 0 0 0 0 0 0 0 0 D 26 
44 M 36 Oligoastrocytoma 5 1 1 1 1 1 0 1 1 A 80 
72 M 45 Astrocytoma 5 1 0 0 0 0 0 0 n.d D 40 
84 F 28 
Diffuse 
astrocytoma 
3 1 0 0 0 1 0 1 n.d. D 51 
Table 4.5. Clinical-pathological features of the 5 LGG included in the study. F = female; M= male; p53 = 
p53 mutation; IDH1 = mutation of IDH1 gene; IDH2 = mutation of IDH2 gene; IDH1/IDH2: mutation of either IDH1 
or IDH2 gene; MGMT = methylation of MGMT promoter; 0 = absent; 1 = present; D = dead; A = alive; OS = overall 
survival; n.d. = not determined. 
 
 
ID Sex 
Age at  
diagnosis 
Histotype 
Ki67 
(%) 
p53 IDH1 IDH2 IDH1/IDH2 MGMT Dead/Alive OS (months) 
85 M 49 
Glioblastoma 
multiforme 
35 0 n.d. n.d. n.d. n.d. D 22 
160 F 72 Glioblastoma 50 0 n.d. n.d. n.d. n.d. D 7 
169 F 66 Glioblastoma 60 1 n.d. n.d. n.d. n.d. D 18 
170 F 70 
Diffuse 
astrocytoma 
15 1 0 0 0 0 D 22 
172 F 76 Glioblastoma 20 1 0 0 0 1 D 16 
Table 4.6. Clinical-pathological features of the 5 HGG included in the study. F = female; M= male; p53 = 
p53 mutation; IDH1 = mutation of IDH1 gene; IDH2 = mutation of IDH2 gene; IDH1/IDH2: mutation of either IDH1 
or IDH2 gene; MGMT = methylation of MGMT promoter; 0 = absent; 1 = present; D = dead; A = alive; OS = overall 
survival; n.d. = not determined. 
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Immunohistochemical analyses demonstrated that all markers were expressed either in LGG, 
(Figure 4.5) or in HGG tissues (Figure
 
 4.6). 
 
Figure 4.5. IL-1β, IL-6 and p65/NFκB expression in 5 LGG samples (20x). 
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Figure 4.6. IL-1β, IL-6 and p65/NFκB expression in HGG samples (20x). 
 
 
However, at a whole, it was apparent that IL-1β, IL-6 and p65/NFκB were expressed at higher 
level in HGG than in LGG. 
Quantitative analysis of the marker expression, performed using Image J program, confirmed  
statistically significant differences in both IL-1β and IL-6 expression between HGG and LGG 
(Figure 4.7). 
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Figure 
 
p65 expression was not significantly different between HGG and LGG. In fact, its expression 
was extremely variable in HGG. In contrast, LGG, with the exception of S25, were mostly 
negative for p65 expression. 
It was interesting to note that S25, a LGG characterized by an extremely poor prognosis, was 
characterized, with respect to the other LGG inserted in the dataset and characterized by a better 
prognosis, by an enhanced expression of all the three markers.  
For this reason, we decided to include all the three markers in the subsequent analyses on a large 
LGG dataset. 
 
4.7. Differences in IL-1β, IL-6 and p65/NFκB expression between high-grade glioma (HGG) and 
low-grade glioma (LGG).  
Results are expressed as mean ± SD, * p<0.05 vs. LGG. 
4.4  IL-1β, IL-6 AND p65 EXPRESSION IN TMA: PATIENTS 
INCLUDED IN THE STUDY 
 
175 low grade glioma samples, included in the TMA, were obtained from the archive available at 
the Pathology Department of the Azienda Ospedaliero-Universitaria of Udine directed by doctor 
Skrap. However, material for immunohistochemical analyses was available for only 161 patients, 
Therefore, our immunohistochemical analyses was restricted to 161 patients. Table 4.7 
summarizes the demographic, clinical and, histological data of the glioma samples analyzed. 
Patients were surgically treated at the Neurosurgery of Udine for a WHO grade II supratentorial 
astrocytoma de novo developed in a period between 1993 and 2013. Tumors were not chemio- or 
radio-treated before surgery. Grade I gliomas were excluded from the analysis because they are 
clinically and genetically different from WHO grade II gliomas.  
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CLINICOPATHOLOGIC FEATURES PATIENTS, NO. % MEDIAN (RANGE) 
SEX     
     MALE 97 60 - 
     FEMALE 64 39 - 
AGE AT SURGERY (YEARS) - - 39 (18-70) 
EXTENT OF RESECTION (%) - - 86 (49-100) 
TUMOR SUBTYPE     
     ASTROCYTOMA 85 52 - 
     OLIGOASTROCYTOMA 
    OLIGODENDROGLIOMA 
 
53 
23 
 
30 
14 
- 
- 
KI67 EXPRESSION (%)   5 (1 – 70) 
     ≤ 4 77 47 - 
     >4 83 50 - 
P53 EXPRESSION (N=158) 105 66 - 
IDH1 MUTATION (N=158) 143 96.8 - 
IDH2 MUTATION (N=158) 4 2.5 - 
IDH1 OR IDH2 MUTATION (N=158) 147 93 - 
CHROMOSOME 1P DELETION (N=155) 56 36 - 
CHROMOSOME 19Q DELETION (N=155) 63 40 - 
CHROMOSOME 1P AND 19Q CO-DELETION (N=155) 51 32 - 
MGMT PROMOTER METHYLATION (N=158) 145 91.7 - 
ATRX EXPRESSION (N=158) 78 49  
P65/NFΚB (N=159) 
NUCLEAR    
- 
 
- 
 
- 
 
- 
 
107 (35.3-156.3) 
7 (0-240) 
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CYTOPLASM           - - 1 (0-3) 
IL-1Β (N=159) 
NUCLEAR 
CYTOPLASM 
- 
 
- 
 
- 
- 
 
- 
 
- 
250 (0-592) 
160 (0-392) 
1 (0-3) 
IL-6 (N=161) - - 75 (27-157.3) 
NUMBER OF MITOSIS/10 HIGH POWER FIELDS - - 1 (0 - 10) 
POST-OPERATIVE CHEMOTHERAPY 68 41 - 
POST-OPERATIVE RADIOTHERAPY 94 57 - 
Table 4.7. Clinicopathologic features of the n=161 low-grade glioma patients. 
60% of patients was male and the median age was 39 years (range 18-70). The most common 
histotype was the astrocytoma (52%) and Ki67 was expressed in more than 4% of cells in 50% 
of patients.  
As regards mutations, more than 90% of grade II gliomas presented IDH1 or IDH2 mutations, 
32% presented 1p/19q co-deletion, 66% presented p53 expression, and 49% presented 
expression of ATRX. MGMT promoter resulted methylated in more than 90% of patients. After 
the surgery intervention, half of the patients were chemo- and/or radio-treated. 
TMA construction allowed evaluating 159 samples of LGG for p65/NFκB and IL-1β and 161 
sample for IL-6, out of 161 samples (Number of total TMA: 14). 
IL-6 expression was analyzed by Image J program quantifying optic mean density of each 
sample for area’s unit. The quantification values ranged from 27-157.3. Figure 4.8 shows IL-6 
expression of a TMA core.  
 
                                                                                                                                                                                                                                                                                                       
                                             A  B            
Figure
As regards p65/NFκB and IL-1β expression, it was evaluated semiquantitatively nuclear and 
cytoplasm positivity.  The score of p65/NFκB and IL-1β nuclear positivity ranged from 0 and 
240 and from 0 and 392, respectively. 44.6% of LGG did not express p65 at nuclear level. 6.9% 
of LGG did not express IL-1β at nuclear level. The p65/NFκB and IL-1β cytoplasm score ranged 
 4.8. IL-6 expression. Representative image of IL-6 expression in TMA. Nuclei are counterstained 
with Hematoxylin of Gill (A: 20x; B: 40x).                 
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from 0 and 3. 20.7% of LGG did not express IL-1β at cytoplasm level. Figure 4.9 and figure 4.10 
show p65/NFκB and IL-1β TMA expression, respectively. 
  
      A  B  C  
Figure
A B C  
 4.9. IL-1β expression. Representative image of a core stained for IL1β(A: 20x). Examples, at 
higher magnification, of LGG with a nuclear(B, 40x) and a cytoplasm (C, 40x) expression of IL1β, 
respectively. Nuclei are counterstained with Hematoxylin of Gill (A: 20x). 
         
 
Figure
4.5 EVALUATION OF THE PROGNOSTIC VALUE OF GOLD 
STANDARD BIOMARKERS 
 4.10. p65/NFκB expression. Representative image of a core stained for p65/NFκB (A: 20x). 
Examples, at higher magnification, of LGG with a nuclear (B, 40x) and a cytoplasm (C, 40x) expression of 
p65/NFκB, respectively. Nuclei are counterstained with Hematoxylin of Gill. 
 
 
When the database was closed, disease progression was observed in 123 patients (76%), 
anaplastic transformation was observed in 102 cases (63%) and 77 patients died (48%). Median 
follow-up in patients still alive was 76 months (range 25-189), median overall survival (OS) was 
65 months, median malignant progression-free-survival (MPFS) was 46 months, and median 
progression free survival (PFS) was 54 months. Estimated rate of  OS, MPFS and PFS at 5 and 
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10 years was, respectively, 66% and 33% for OS, 46% and 17% for MPFS and 37% and 7% for 
PFS.  
OVERALL SURVIVAL  
As illustrated in table 4.8, prognostic factors which at the univariate analysis (p<0,005) were 
positively associated with overall survival (OS) were the extent of tumor resection (EOR), the 
patient’s clinical status evaluated as Karnosky Performance Status (KPS) and the presence of 
mutated IDH1 gene. Conversely, the age and the Ki67 expression ≥  4 were associated with a 
poor prognosis.  
At the multivariate Cox analysis, independent predictors of OS were Ki67 (hazard ratio –HR- 
2.34, confidence interval at 95% –CI95%- 1.45-3.76, p=0.000), the extent of tumor resection 
(HR 0.93, CI95% 0.92-0.95, p=0.000), the KPS (HR 0.94, CI95% 0.91-0.97, p=0.000) and 
mutated IDH1 gene (HR 0.40, CI95% 0.19-0.84, p=0.000). 
 
TUMOR PROGRESSION 
As illustrated in table 4.8, prognostic factors which at the univariate analysis (p<0,005) were 
positively associated with progression free survival (PFS) were the extent of tumor resection 
(EOR) and the patient’s clinical status (KPS). Conversely, the Ki67 expression ≥ 4 and the 
presence of p53 mutation were associated with an high risk of progression.  
At the multivariate Cox analysis, independent predictors of PFS were Ki67 (HR 1.55, CI95% 
1.06-2.25, p=0.022), the extent of tumor resection (HR 0.96, CI95% 0.94-0.97, p=0.000), and 
p53 expression (HR 1.82, CI95% 1.19-2.80, p=0.006). 
 
MALIGNANT TRANSFORMATION 
As illustrated in table 4.8, prognostic factors which at the univariate analysis (p<0,005) were 
positively associated with malignant progression-free-survival (MPFS) were the extent of tumor 
resection (EOR) and the patient’s clinical status (KPS). Conversely, the Ki67 expression ≥4 was  
associated with an high risk of progression.  
At the multivariate Cox analysis, independent predictors of MPFS were Ki67 (HR 1.69, CI95% 
1.13-2.53, p=0.010), the extent of tumor resection (HR 0.95, CI95% 0.94-0.97, p=0.000), and the 
KPS (HR 0.95, CI95% 0.94-0.97, p=0.000). 
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Table 4.8. Univariate analysis of prognostic value of clinical and histological parameters with overall 
survival (OS), progression-free survival (PFS) and malignant progression-free survival (MPFS) in 161 
patients with low-grade glioma. Abbreviations: HR = hazard ratio; CI = confidence interval; EOR = extent 
of surgical resection; KPS = Karnosky Performance Status. p<0.05 statistically significant. 
 OS PFS MPFS 
 HR 95% CI p HR 95% CI p HR 95% CI p 
AGE (MODELED AS 
CONTINUOUS 
VARIABLE) 
1.02 1.00-1.04 0.019 1.00 0.99-1.02 0.763 1.01 1.00-1.03 0.194 
SEX (F VS M) 0.66 0.41-1.07 0.087 0.95 0.66-1.38 0.797 0.70 0.46-1.05 0.081 
KPS (MODELED AS 
CONTINUOUS 
VARIABLE) 
0.94 0.91-0.97 <0.0001 0.97 0.94-0.99 0.043 0.95 0.92-0.98 <0.0001 
% EOR (MODELED 
AS CONTINUOUS 
VARIABLE) 
0.93 0.91-0.95 <0.0001 0.96 0.94-0.97 <0.0001 0.95 0.94-0.97 <0.0001 
HYSTOTYPE 
(OLIGOASTROCYTO
MA VS OTHERS) 
0.95 0.58-1.54 0.840 1.06 0.72-1.55 0.787 1.07 0.73-1.59 0.726 
% KI67 > 4 VS ≤ 4 2.10 2.32-3.35 0.002 1.44 1.01-2.06 0.046 1.64 1.01-2.43 0.015 
NUMBER OF 
MITOSIS (MODELED 
AS CONTINUOUS 
VARIABLE) 
1.02 0.88-1.19 0.782 1.02 0.90-1.16 0.727 1.04 0.92-1.17 0.558 
IDH1 MUTATION 
(YES VS NO) 
0.48 0.24-0.97 0.041 1.10 0.57-2.15 0.771 0.66 0.34-1.28 0.213 
IDH2 MUTATION 
(YES VS NO) 
1.35 0.33-5.51 0.678 1.88 0.69-5.13 0.218 1.75 0.55-5.55 0.340 
IDH1 OR IDH2 
MUTATION (YES VS 
NO) 
0.42 0.19-0.93 0.009 1.54 0.66-3.57 0.324 0.71 0.32-1.56 0.390 
P53 MUTATION 
(YES VS NO) 
0.90 0.55-1.47 0.670 1.65 1.09-2.48 0.017 1.30 0.84-2.02 0.237 
ATRX EXPRESSION 
(YES VS NO) 
1.44 0.91-2.28 0.119 0.84 0.58-1.22 0.356 1.08 0.72-1.60 0.714 
MGMT 
PROMOTER 
METHYLATION 
(YES VS NO) 
0.65 0.26-1.61 0.347 1.28 0.58-2.80 0.534 0.70 0.30-1.56 0.391 
CHROMOSOME 1P 
DELETION (YES VS 
NO) 
0.86 0.52-1.40 0.537 0.71 0.48-1.06 0.094 0.74 0.48-1.14 0.170 
CHROMOSOME 
19Q   DELETION 
(YES VS NO) 
1.09 0.68-1.75 0.724 0.87 0.59-1.27 0.457 0.91 0.60-1.37 0.640 
CHROMOSOME 
1P/19Q CO-
DELETION (YES VS 
NO) 
0.91 0.55-1.51 0.706 0.75 0.50-1.13 0.170 0.82 0.53-1.27 0.370 
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4.6 EVALUATION OF THE PROGNOSTIC VALUE OF IL-1β, IL-6 AND 
p65 
 
TMA analysis of IL-1β, IL-6 and p65/NFκB expression was assessed by using the Cox 
regression. Table 4.9 illustrates Cox univariate analysis of IL-1β, IL-6 and p65/NFκB. At the 
univariate analysis, nuclear and cytoplasm IL-1β expressions did not statistically correlate with 
OS, PFS and MPFS, while IL-6 expression had a protective effect with OS and MPFS. The 
prognostic factor associated with a poor OS was the nuclear p65 expression (Table 4.9). This 
result confirmed the previous evaluation of p65 expression in a LGG characterized by a poor 
prognosis; it is interesting to note that only the nuclear expression of P65/NFkB was endowed 
with a prognostic significance, indicating that the protein localization is fundamental for the 
prognostic value.  
 
Table 4.9. Analysis of p65/NFκB, IL-1β and IL-6 expression with OS, PFS and MPFS in 161 patients with 
low-grade gliomas. Abbreviations: HR: hazard ratio, CI: confidence interval, OS: overall survival, PFS: 
progression free survival, MPFS: malignant progression free survival. p<0.05 statistically significant. 
At the multivariate Cox analysis, including all factors resulted to be significantly associated with 
prognosis at the univariate analysis, nuclear p65 resulted to be an independent predictive factor 
of OS (HR 1.006,CI 95% 1.002-1.011, p=0.002), together with Ki67 (HR 2.324, CI95% 1.391-
3.881, p=0.001), the extent of tumor resection (HR 0.924, IC95% 0.906-0.943, p=0.000), the 
KPS (HR 0.940, IC95% 0.906-0.974, p=0.001), and mutated IDH1 gene (HR 0.335, IC95% 
0.149-0.751, p=0.008). 
Moreover, nuclear p65 resulted to be an independent predictive factor of MPFS (HR 1.004, 
IC95% 1.000-1.008, p=0.028), together with Ki67 (HR 1.574, IC95% 1.044-2.374, p=0.003), the 
extent of tumor resection (HR 0.951, IC95% 0.936-0.967, p=0.000) and KPS (HR 0.949, IC95% 
0.921-0.979, p=0.001). 
The  multivariate Cox analysis demonstrated that IL6 do not represent an independent predictive 
factor of OS and of MPFS.  
 
 OS PFS MPFS 
 HR 95% CI p HR 95% CI p HR 95% CI p 
GLOBAL P65  1.003 0.994-1.012 0.499 0.999 0.992-1.006 0.772 1.002 0.994-1.010 0.612 
NUCLEAR P65  1.004 1.000-1.008 0.044 1.002 0.999-1.006 0.230 1.003 1.000-1.007 0.087 
GLOBAL IL6  0.983 0.972-0.995 0.005 0.992 0.983-1.000 0.061 0.984 0.979-0.999 0.032 
GLOBAL IL1B  1.000 0.999-1.002 0.684 1.000 0.995-1.001 0.942 1.001 1.000-1.002 0.184 
NUCLEAR IL1B  1.001 0.999-1.002 0.440 1.000 0.995-1.002 0.728 1.001 1.000-1.003 0.120 
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5. DISCUSSION  
 
Translational medicine aims at transferring advances in basic science research into new 
approaches for diagnosis and treatment of diseases. With this goal, our research group used a 
population of stem cell, isolated from human glioma, named Glioma-Associated Stem Cells 
(GASC), such an approach of personalized medicine to identify new prognostic and predictive 
factors that lend to personalized therapies (79). 
GASC represent an in vitro model of the glioma microenvironment and they have a strong 
prognostic value in low grade glioma since their surface immunophenotype can predict patients’ 
overall survival (OS) and malignant  transformation risk (79).  
Emerging studies highlight the importance of the tumor microenvironment in tumor progression 
(70) which can be considered a potential target for the development of new therapeutic strategies 
(101). 
For this reason, low grade glioma (WHO grade II), characterized by a better prognosis with 
respect to the high-grade ones, represent an important challenge for clinicians because: 1) 
complete surgical resection is quite impossible and about 70% of tumors transforms into 
anaplastic forms within 5-10 years with aggressive clinical manifestation and fatal outcome (27); 
2) some of LGG progress to high-grade glioma and criteria for a correct patients’ prognostic 
stratification don’t exist (29); 3) current adjuvant therapies (radio- and chemo-therapies) cause 
neurocognitive deficits which affect negatively the patient’s quality of life and well-being. 
Recently, two independent studies of genome-wide molecular analysis have reported the clinical 
value of 1p/19q co-deletions, IDH1/2, TERT, TP53, and ATRX mutations in grade II and grade 
III gliomas. Both groups proposed a classification based on a combination of these molecular 
markers: the first study (14) identified a combination of presence/absence of IDH mutations, 
1p/19q co-deletions and TP53 status meanwhile the second study (15) identified a combination of 
presence/absence of 1p/19q co-deletions, IDH1/2 mutations and TERT mutations. Both papers 
have demonstrated that the presence of IDH1/2 mutations is a factor of good prognosis.  
As described in the previous paragraphs, our group isolated GASC from 40 cases of grade II 
glioma. We demonstrated that a score based on GASC characterization was the only independent 
predictor of both OS and MPFS, outperforming all the available criteria in stratifying LGG 
patients, such IDH1/2 mutations, 1p/19q co-deletions and TP53 status (79). 
The use of GASC as predictor factor in LGG requires the presence of cellular culture 
laboratories and few pathology departments are provided with this type of laboratory. To 
introduce new markers related to the tumor microenvironment in the clinical practice, we have 
decided to analyze the gene expression profile of GASC to search for new key molecules and 
detect them at tissue level by immunohistochemical assays. In collaboration with the Institute of 
Applied Genomics, we decided, therefore, to sequence the exome of two groups of GASC lines 
obtained from glioma with different prognosis: glioma without malignant transformation after 7 
years from treatment and glioma transformed in high grade forms within 48 months from 
treatment. 
This was possible because we have built, in collaboration with the neurosurgery department of 
doctor Skrap, a bio-repository that includes cryopreserved lines of GSC (n=40), and GASC from 
both LGG (n=80) and HGG (n=100). 
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Thawed GASC lines continued to possess features of stemness (mesenchymal surface 
phenotype, expression of pluripotent state-specific transcription factors expression and 
intermediate filaments related to an undifferentiated phenotype and aberrant anchorage-
independent growth. These evidences confirmed the value of our protocols optimized not only 
for the isolation but also for the cryopreservation of glioma cell lines. 
The analysis of genes differentially expressed pointed out that the transcriptome of GASC 
obtained from glioma with a poor prognosis contains elements typical of the inflammatory 
response and of the so-called senescence-associated secretory phenotype (SASP) (102). 
Senescence is now increasingly considered to be an integrated and widespread component that is 
potentially important for tumour development, tumour suppression and the response to therapy 
(103). The core aspect of the senescent phenotype is a stable state of cell cycle arrest. However, 
this feature conceals a highly active metabolic cell state with diverse functionality. Both the cell-
autonomous and the non-cell-autonomous activities of senescent cells create spatiotemporally 
dynamic and context-dependent tissue reactions (103). For example, the senescence-associated 
secretory phenotype (SASP) provokes not only tumour-suppressive but also tumour-promoting 
responses (103). 
It has long been considered an important element the development of an inflammatory 
microenvironment for the tumor progression, particularly in the initiation and progression of 
glioblastoma. This tumor is surrounded by a pool of pro-inflammatory cytokines, such IL-1β, IL-
6 and IL-8, which activate the inflammatory pathways of JAK, p38 MAPK and JNK (100). 
Concordantly, upstream regulators analysis of genes differentially expressed between GASC 
from LGG with a good prognosis and LGG with a bad prognosis, by using Ingenuity Pathway 
Analysis (in collaboration with LNCIB), pointed out the presence of some cytokines and 
transcriptional regulators. 
We selected three factors representatives of different inflammatory pathway, IL-1β, IL-6 and 
p65, a component of the heterodimer NFκB, from the upstream regulators list, on the base of 
their probability to activate a molecular signature characterizing GASC from LGG with a bad 
prognosis. 
IL-1 may directly stimulate glioma cell proliferation and induce the secretion of other cytokines 
like IL-6 and IL-8 by an autocrine loop (85). IL-1, IL-6 and IL-8 share the capacity to induce the 
expression and secretion of MMP-2, MMP-9 in normal and tumor cells (86), (87), (88). Thus, these 
factors may contribute to invasion of glioma cells through the induction of matrix degrading 
proteinases. 
Recent studies demonstrate that IL-1 is an inducer of pro-angiogenesis and pro-invasion factors 
such as VEGF and MMPs in glioblastoma cells (104), (105).  
Similarly, IL-6 act in a pracrine loop in the tumour microenvironment stimulating angiogenesis 
by inducing endothelial cell and pericyte proliferation and migration, generating an invasion 
permissive environment (80). 
The transcriptional factor NFκB performs an important role for the production of a secretome 
enriched in inflammatory cytokines in senescent cells. NFκB activation in senescent cells can be 
induced by different mechanisms: response to a DNA damage, Retinoic Acid-Inducible Gene 
1(RIG-1) inflammasome, p38 MAPK pathway induced by stress, TGFβ and inflammatory 
cytokines (such IL-1β) (106). 
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IL-1β, IL-6 and p65 have been studied in high-grade glioma (107) (108) (109) but not in low-grade 
glioma, therefore we have evaluated their expression at tissue level.  
Firstly, we optimized the immunohistochemical assay on glioma sections belonging to a group of 
LGG (n=5) and to a group of HGG (n=5), to check a possible difference in the expression of the 
selected factors.  
Expression quantification confirmed a high production of IL-1β and IL-6 in high-grade glioma. 
These cytokines were expressed in significantly a lower quantity in low-grade glioma; however, 
it was interesting to note that the low-grade glioma sample characterized by with a poor 
prognosis was characterized by a high expression of IL-1β and IL-6. 
Differently, p65 expression was extremely variable among high-grade glioma and was 
particularly high in the LGG with a bad prognosis. Recently, it has been found that NFκB 
expression in HGG can be associated with chemoresistance, thus identifying a group of HGG 
characterized by a poor prognosis (107). 
Besides, it was demonstrated that neurosphere, isolated from proneural glioblastoma, can be 
induced to a mesenchymal phenotype in an NFκB-dependent fashion, suggesting that NFκB 
expression can be associated with an aggressive phenotype (108).  
Since in our data IL-1β, IL-6 and p65 expression was particularly high in the LGG with a poor 
prognosis, we considered including these markers in the evaluation of the case study available at 
the Neurosurgery Department of Azienda Ospedaliero-Universitaria of Udine and to test their 
possible prognostic value. 
We constructed 14 TMA containing 161 samples of LGG and we evaluated with 
immunohistochemical assays the expression of IL-1β, IL-6 and p65. The statistical analysis 
confirmed that nuclear p65 expression is an independent predictor factor of OS and MPFS in 
LGG and this evidence supports the use of GASC as a model to search new prognostic factors. 
The nuclear localization of p65 indicates that the nuclear translocation of this transcription factor 
is fundamental for the activation of pathways that increase, in glioma, invasiveness as well 
resistance to therapies. In fact when p65 binds to DNA activates factors implicated in the 
inflammatory response (IL-6 and IL-8) and anti-apoptotic genes (cIAP2, Bcl-2) (89). Moreover, 
p65 is implicated in the transcriptional activation of the matrix metalloproteinase-9 (MMP-9) 
promoter in human glioma cells (109), demonstrating a role in the tumor invasiveness. 
However, our study demonstrates that IL-6 expression has a protective effect with OS and MPFS 
and this result is in contrast with the nuclear expression of p65, because it induces the expression 
of IL-6 (110); then the multivariate analysis of our study demonstrated that IL6 do not represent an 
independent predictive factor of OS and of MPFS. This evidence suggests that the modulation of 
inflammatory cytokines is extremely complex: IL-6 expression is regulated by NFκB and also by 
Notch, S1PR1 and STAT3 phosphorilation (111). Moreover, recent studies affirm that single 
nucleotide polymorphisms (SNP) in the promoter region of IL-6 are associated with the 
production of this cytokine and with cancer risk (112).  
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6. CONCLUSION AND FUTURE PERSPECTIVES 
 
We have studied gene expression profile of GASC obtained from gliomas with different 
prognosis and we have found that GASC from gliomas with a malignant progression are 
characterized by an inflammatory transcriptome which includes cytokines such IL-1β and IL-6 
and transcriptional regulator like NFκB/p65.  
We have evaluated the expression of IL-1β, IL-6 and NFκB/p65 at tissue level optimizing an 
immunohystochemical assay on high-grade and low-grade gliomas. The three markers were 
expressed at high levels in high-grade gliomas and in a low-grade glioma with a bad prognosis. 
Since low-grade gliomas expressed IL-1β and IL-6 at quantifiable levels, we decided to validate 
the obtained results on the case study of LGG available in our department. 
The analyses of our immunohystochemical assays suggest nuclear p65 as an independent 
predictor of OS and MPFS.  
These promising data will enable us to extend our analyses to the case study of LGG available at 
the Neurosurgery Department of Azienda Ospedaliero-Universitaria of Udine. We have one of 
the most comprehensive case study of tissues obtained from patients with LGG in Europe and 
the corresponding clinical database is updated continuously. In particular, we have DNA, RNA 
and TMA of about 250 consecutive samples of supratentorial LGG characterized from a clinical 
point of view (age, sex, therapy, surgery, overall survival, progression free survival, malignant 
progression free survival), from a neuroradiologic point of view (extent of tumor resection, 
tumor bulk before the surgery and tumor bulk at the follow-up) and from a histologycal-
molecular point of view (histotype, Ki67 and p53 expression, 1p-19q co-deletion, IDH1/2 
mutation, MGMT promoter methylation).  
Definition of new prognostic/predictive factors in LGG can provide: 
 To clinician new instruments for the clinical management of the patients 
 A new antibody panel useful for the immunohistochemical analyses for pathology 
departments with a low cost and a high benefit for patients and hospitals. 
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